<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1426" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1426/" /><meta name="ncbi_pagename" content="Beta-Thalassemia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Beta-Thalassemia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Beta-Thalassemia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/01/25" /><meta name="citation_author" content="Raffaella Origa" /><meta name="citation_pmid" content="20301599" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1426/" /><meta name="citation_keywords" content="Cooley's Anemia" /><meta name="citation_keywords" content="Mediterranean Anemia" /><meta name="citation_keywords" content="Cooley's Anemia" /><meta name="citation_keywords" content="Mediterranean Anemia" /><meta name="citation_keywords" content="Thalassemia Major" /><meta name="citation_keywords" content="Thalassemia Intermedia" /><meta name="citation_keywords" content="Thalassemia Minor" /><meta name="citation_keywords" content="Hemoglobin subunit beta" /><meta name="citation_keywords" content="HBB" /><meta name="citation_keywords" content="Beta-Thalassemia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Beta-Thalassemia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Raffaella Origa" /><meta name="DC.Date" content="2018/01/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1426/" /><meta name="description" content="Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis." /><meta name="og:title" content="Beta-Thalassemia" /><meta name="og:type" content="book" /><meta name="og:description" content="Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1426/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/b-thal/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1426/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE881B6CE04117F10000000000EF005D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1426_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1426_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bpan/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bietti-cd/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1426_"><span class="title" itemprop="name">Beta-Thalassemia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Cooley's Anemia, Mediterranean Anemia</div><p class="contrib-group"><span itemprop="author">Raffaella Origa</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1426_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1426_ai__"><div class="contrib half_rhythm"><span itemprop="author">Raffaella Origa</span>, MD<div class="affiliation small">Dipartimento di Scienze Mediche e Sanit&#x000e0; Pubblica<br />Universit&#x000e0; degli Studi di Cagliari<br />Ospedale Pediatrico Microcitemico Antonio Cao<br />Cagliari, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.acinu@agiro.alleaffar" class="oemail">ti.acinu@agiro.alleaffar</a><span style="unicode-bidi: bidi-override; direction: ltr;">; </span><a href="mailto:dev@null" data-email="ti.boa@agiro.alleaffar" class="oemail">ti.boa@agiro.alleaffar</a><div></div></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 28, 2000</span>; Last Update: <span itemprop="dateModified">January 25, 2018</span>.</p><p><em>Estimated reading time: 40 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="b-thal.Summary" itemprop="description"><h2 id="_b-thal_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Beta-thalassemia (&#x003b2;-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.</p><p>Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis.</p><p>Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of &#x003b2;-thalassemia relies on measuring red blood cell indices that reveal microcytic hypochromic anemia, nucleated red blood cells on peripheral blood smear, hemoglobin analysis that reveals decreased amounts of HbA and increased amounts of hemoglobin F (HbF) after age 12 months, and the clinical severity of anemia. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>HBB</i> (the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding the hemoglobin subunit beta) on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> may be useful for diagnosis in at-risk individuals under age 12 months who have a positive or suggestive <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> result and/or unexplained microcytic hypochromic anemia with anisopoikilocytosis and nucleated red blood cells on peripheral blood smear.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i></p><ul><li class="half_rhythm"><div>Thalassemia major. Regular transfusions correct the anemia, suppress erythropoiesis, and inhibit increased gastrointestinal absorption of iron. Bone marrow transplantation (BMT) from an HLA-identical sib represents an alternative to traditional transfusion and chelation therapy. Cord blood transplantation from a related donor offers a good probability of a successful cure and is associated with a low risk for graft-vs-host disease.</div></li><li class="half_rhythm"><div>Thalassemia intermedia. Symptomatic therapy based on splenectomy in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> red cell transfusions in some, folic acid supplementation, and iron chelation.</div></li></ul><p><i>Prevention of secondary complications:</i> Assessment of iron overload through one or more of the following: serum ferritin concentration, liver biopsy, magnetic biosusceptometry, and MRI techniques; prevention of transfusional iron overload with adequate iron chelation therapy (i.e., desferroxamine B, deferiprone, deferasirox); assessment of myocardial siderosis by MRI and monitoring of cardiac function; treatment of osteoporosis, including consideration of bisphosphonate therapy.</p><p><i>Surveillance:</i> Thalassemia major: monitoring of the effectiveness/side effects of transfusion therapy and chelation therapy in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of all ages by monthly physical examination; trimonthly assessment of liver function tests, determination of serum ferritin concentration, and evaluation of growth and development (during childhood); annual evaluation of eyes, hearing, heart, endocrine function (thyroid, endocrine pancreas, parathyroid, adrenal, pituitary), liver (ultrasound examination), and myocardial and liver MRI. In adults: bone densitometry to assess for osteoporosis; serum alpha-fetoprotein concentration for early detection of hepatocarcinoma in those with hepatitis C and iron overload; regular gallbladder echography for early detection of cholelithiasis for those at risk.</p><p><i>Agents/circumstances to avoid:</i> Alcohol consumption, iron-containing preparations.</p><p><i>Evaluation of relatives at risk</i>: If the pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk sibs should be offered to allow for early diagnosis and appropriate treatment. Hematologic testing can be used if the pathogenic variants in the family are not known.</p><p><i>Pregnancy management:</i> Women with thalassemia intermedia who have never received a blood transfusion or who received a minimal quantity of blood are at risk for severe alloimmune anemia if blood transfusions are required during pregnancy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>The &#x003b2;-thalassemias are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Heterozygotes (i.e., carriers) may be slightly anemic but are clinically asymptomatic. Carriers are often referred to as having thalassemia minor (or &#x003b2;-thalassemia minor). Carrier testing for individuals at risk (including family members, gamete donors, and members of at-risk ethnic groups) is possible. Once both <i>HBB</i> pathogenic variants have been identified in a couple at risk, prenatal testing and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="b-thal.GeneReview_Scope"><h2 id="_b-thal_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="b-thal.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_b-thal.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Beta-Thalassemia: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_b-thal.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Thalassemia major</div></li><li class="half_rhythm"><div>Thalassemia intermedia</div></li><li class="half_rhythm"><div>Thalassemia minor</div></li></ul>
</td></tr></tbody></table></div></div></div><div id="b-thal.Diagnosis"><h2 id="_b-thal_Diagnosis_">Diagnosis</h2><div id="b-thal.Suggestive_Findings"><h3>Suggestive Findings</h3><p><b>Beta-thalassemia (&#x003b2;-thalassemia) major</b>
<b>should be suspected</b> in an infant or child younger than age two years with the following clinical or <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> findings:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Clinical findings</b></div><ul><li class="half_rhythm"><div>Severe microcytic anemia</div></li><li class="half_rhythm"><div>Mild jaundice</div></li><li class="half_rhythm"><div>Hepatosplenomegaly</div></li></ul><div class="half_rhythm">Note: If untreated, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children usually manifest failure to thrive and expansion of the bone marrow to compensate for ineffective erythropoiesis.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Newborn screening findings.</b> A positive or suggestive screen done through <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (i.e., through capillary electrophoresis, <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a>, or high-performance liquid chromatography on newborn blood spots)</div></li></ul><p><b>Thalassemia intermedia should be suspected</b> in individuals who present at a later age with similar but milder clinical findings. Individuals with thalassemia intermedia do not require regular treatment with blood transfusion.</p><p><b>Thalassemia minor</b> is usually clinically asymptomatic, but sometimes a mild anemia is present.</p></div><div id="b-thal.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of &#x003b2;-thalassemia <b>is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> older than age 12 months</b> based on the hematologic findings of microcytic hypochromic anemia (<a class="figpopup" href="/books/NBK1426/table/b-thal.T.red_blood_cell_indices_in_betat/?report=objectonly" target="object" rid-figpopup="figbthalTredbloodcellindicesinbetat" rid-ob="figobbthalTredbloodcellindicesinbetat">Table 1</a>), anisopoikilocytosis with nucleated red blood cells on peripheral blood smear, and hemoglobin analysis that reveals decreased amounts or complete absence of hemoglobin A and increased amounts of hemoglobin F (<a class="figpopup" href="/books/NBK1426/table/b-thal.T.hemoglobin_patterns_in_betathal/?report=objectonly" target="object" rid-figpopup="figbthalThemoglobinpatternsinbetathal" rid-ob="figobbthalThemoglobinpatternsinbetathal">Table 2</a>).</p><p>The diagnosis of &#x003b2;-thalassemia <b>is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> younger than age 12 months</b> based on the following findings:</p><ul><li class="half_rhythm"><div>Positive or suggestive <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> result</div><ul><li class="half_rhythm"><div>The diagnosis of &#x003b2;<sup>0</sup>-thalassemia (in which no beta-globin protein is produced) can be made at birth by detecting a complete absence of hemoglobin A.</div></li><li class="half_rhythm"><div>Definitive diagnosis of &#x003b2;<sup>+</sup>-thalassemia (in which beta-globin protein is produced but at a reduced level) by these techniques is not possible in the newborn period because the diminished amount of hemoglobin A overlaps the range for normal babies.</div></li></ul></li><li class="half_rhythm"><div>Microcytic hypochromic anemia with anisopoikilocytosis and nucleated red blood cells on peripheral blood smear</div></li><li class="half_rhythm"><div>Biallelic pathogenic variants in <i>HBB</i> identified on <a href="#b-thal.Molecular_Genetic_Testing">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1426/table/b-thal.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figbthalTmoleculargenetictestingused" rid-ob="figobbthalTmoleculargenetictestingused">Table 3</a>)</div></li></ul><div id="b-thal.Hematologic_Findings"><h4>Hematologic Findings</h4><p><b>Red blood cell indices</b> show microcytic anemia (<a class="figpopup" href="/books/NBK1426/table/b-thal.T.red_blood_cell_indices_in_betat/?report=objectonly" target="object" rid-figpopup="figbthalTredbloodcellindicesinbetat" rid-ob="figobbthalTredbloodcellindicesinbetat">Table 1</a>).</p><div id="b-thal.T.red_blood_cell_indices_in_betat" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Red Blood Cell Indices in Beta-Thalassemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.T.red_blood_cell_indices_in_betat/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.T.red_blood_cell_indices_in_betat_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_1" style="text-align:left;vertical-align:middle;">Red Blood Cell Index</th><th id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Normal&#x000a0;<sup>1</sup></th><th id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Affected</th><th id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carrier&#x000a0;<sup>1</sup></th></tr><tr><th headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2" id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Male</th><th headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2" id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Female</th><th headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_3" id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b2;-Thal&#x000a0;Major</th><th headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_4" id="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b2;-Thal Minor</th></tr></thead><tbody><tr><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mean corpuscular volume (MCV fl)</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">89.1&#x000b1;5.01</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">87.6&#x000b1;5.5</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_3 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50-70</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_4 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;79</td></tr><tr><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mean corpuscular hemoglobin (MCH pg)</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.9&#x000b1;1.9</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.2&#x000b1;2.1</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_3 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12-20</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_4 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;27</td></tr><tr><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemoglobin (Hb g/dL)</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15.9&#x000b1;1.0</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_2 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14.0&#x000b1;0.9</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_3 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;7</td><td headers="hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_1_4 hd_h_b-thal.T.red_blood_cell_indices_in_betat_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Males: 11.5-15.3<br />Females: 9.1-14</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="b-thal.TF.1.1"><p class="no_margin">Data from <a class="bk_pop" href="#b-thal.REF.galanello.1979.33">Galanello et al [1979]</a></p></div></dd></dl></div></div></div><p><b>Peripheral blood smear</b></p><ul><li class="half_rhythm"><div>Affected individuals demonstrate the red blood cell (RBC) morphologic changes of microcytosis, hypochromia, anisocytosis, poikilocytosis (spiculated tear-drop and elongated cells), and nucleated red blood cells (i.e., erythroblasts). The number of erythroblasts is related to the degree of anemia and is markedly increased following splenectomy.</div></li><li class="half_rhythm"><div>Carriers demonstrate reduced mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) (<a class="figpopup" href="/books/NBK1426/table/b-thal.T.red_blood_cell_indices_in_betat/?report=objectonly" target="object" rid-figpopup="figbthalTredbloodcellindicesinbetat" rid-ob="figobbthalTredbloodcellindicesinbetat">Table 1</a>), and RBC morphologic changes that are less severe than in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Erythroblasts are normally not seen.</div></li></ul><p><b>Qualitative and quantitative hemoglobin analysis</b> (by cellulose acetate electrophoresis and DE-52 microchromatography or HPLC) identifies the amount and type of hemoglobin present. The following hemoglobin (Hb) types are most relevant to &#x003b2;-thalassemia:</p><ul><li class="half_rhythm"><div>Hemoglobin A (HbA): two globin alpha chains and two globin beta chains (&#x003b1;<sub>2</sub>&#x003b2;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin F (HbF): two globin alpha chains and two globin gamma chains (&#x003b1;<sub>2</sub>&#x003b3;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin A<sub>2</sub> (HbA<sub>2</sub>): two globin alpha chains and two globin delta chains (&#x003b1;<sub>2</sub>&#x003b4;<sub>2</sub>)</div></li></ul><p>The hemoglobin pattern in &#x003b2;-thalassemia varies by &#x003b2;-thalassemia type (<a class="figpopup" href="/books/NBK1426/table/b-thal.T.hemoglobin_patterns_in_betathal/?report=objectonly" target="object" rid-figpopup="figbthalThemoglobinpatternsinbetathal" rid-ob="figobbthalThemoglobinpatternsinbetathal">Table 2</a>).</p><div id="b-thal.T.hemoglobin_patterns_in_betathal" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Hemoglobin Patterns in Beta-Thalassemia (Age &#x0003e;12 Months)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.T.hemoglobin_patterns_in_betathal/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.T.hemoglobin_patterns_in_betathal_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_1" style="text-align:left;vertical-align:middle;">Hemoglobin Type</th><th id="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_2" style="text-align:left;vertical-align:middle;">Normal&#x000a0;<sup>1</sup></th><th id="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Affected</th><th id="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carrier</th></tr><tr><th headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3" id="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">&#x003b2;&#x000ba;-Thal Homozygotes&#x000a0;<sup>2</sup></th><th headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3" id="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b2;<sup>+</sup>-Thal Homozygotes or &#x003b2;<sup>+</sup>/&#x003b2;&#x000ba; Compound Heterozygotes&#x000a0;<sup>3</sup></th><th headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_4" id="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b2;-Thal Minor</th></tr></thead><tbody><tr><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbA</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%-98%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-30%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_4 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">92%-95%</td></tr><tr><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbF</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%-98%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%-90%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_4 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.5%-4%</td></tr><tr><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbA<sub>2</sub></td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-3%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-5%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_3 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-5%</td><td headers="hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_1_4 hd_h_b-thal.T.hemoglobin_patterns_in_betathal_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;3.5%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="b-thal.TF.2.1"><p class="no_margin">Data from <a class="bk_pop" href="#b-thal.REF.telen.1999">Telen &#x00026; Kaufman [1999]</a></p></div></dd><dt>2. </dt><dd><div id="b-thal.TF.2.2"><p class="no_margin">&#x003b2;&#x000ba;-thalassemia: complete absence of globin beta chain production</p></div></dd><dt>3. </dt><dd><div id="b-thal.TF.2.3"><p class="no_margin">&#x003b2;<sup>+</sup>-thalassemia: variable degree of reduction of globin beta chain synthesis</p></div></dd></dl></div></div></div><p>Hemoglobin electrophoresis and HPLC also detect other hemoglobinopathies (S, C, E, O<sub>Arab</sub>, Lepore) that may interact with &#x003b2;-thalassemia.</p><p>Click <a href="/books/NBK1426/bin/b-thal-iv-synthesis.pdf">here</a> (pdf) for information on the results of in vitro synthesis of radioactive labeled globin chains in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="b-thal.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>The recommended <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approach for beta-thalassemia is <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm">Sequence analysis of <i>HBB</i> is performed first and followed by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Note: Analysis of <i>HBB</i> is complicated by the presence of highly homologous <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> family members as well as a <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a>, <i>HBBP1</i>; therefore, any assay that examines <i>HBB</i> sequence must be validated to ensure specificity to the active gene (see <a href="#b-thal.Molecular_Genetics">Molecular Genetics</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">In at-risk populations (see <a class="figpopup" href="/books/NBK1426/table/b-thal.T.selected_hbb_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figbthalTselectedhbbpathogenicvariant" rid-ob="figobbthalTselectedhbbpathogenicvariant">Table 4</a>), <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a> can be performed first based on ancestry since the prevalent pathogenic variants are limited in each at-risk population.</div></li></ul><div id="b-thal.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Beta-Thalassemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBB</i></td><td headers="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Almost 100%</td></tr><tr><td headers="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_b-thal.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="b-thal.TF.3.1"><p class="no_margin">See <a href="/books/NBK1426/#b-thal.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="b-thal.TF.3.2"><p class="no_margin">See <a href="#b-thal.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="b-thal.TF.3.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="b-thal.TF.3.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="b-thal.TF.3.5"><p class="no_margin"><a class="bk_pop" href="#b-thal.REF.harteveld.2005.922">Harteveld et al [2005]</a>, <a class="bk_pop" href="#b-thal.REF.shooter.2015.128">Shooter et al [2015]</a>, <a class="bk_pop" href="#b-thal.REF.reading.2016.1153">Reading et al [2016]</a></p></div></dd></dl></div></div></div></div></div></div><div id="b-thal.Clinical_Characteristics"><h2 id="_b-thal_Clinical_Characteristics_">Clinical Characteristics</h2><div id="b-thal.Clinical_Description"><h3>Clinical Description</h3><p>Beta-thalassemia (&#x003b2;-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.</p><p>The phenotypes of the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> &#x003b2;-thalassemias include thalassemia major and thalassemia intermedia. The clinical severity of the &#x003b2;-thalassemia syndromes depends on the extent of alpha globin chain / non-alpha globin chain (i.e., &#x003b2;+ &#x003b3;) imbalance. The non-assembled alpha globin chains that result from unbalanced alpha globin chain / non-alpha globin chain synthesis precipitate in the form of inclusions. These alpha globin chain inclusions damage the erythroid precursors in the bone marrow and in the spleen, causing ineffective erythropoiesis. The bone marrow is extremely cellular, mainly as a result of marked erythroid hyperplasia, with a myeloid/erythroid ratio reversed from the normal (3 or 4) to 0.1 or less. However, bone marrow examination is usually not necessary for diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>Individuals with thalassemia major usually come to medical attention within the first two years of life; they subsequently require regular red blood cell transfusions to survive. Those who present later and do not regularly require transfusion are said to have thalassemia intermedia.</p><div id="b-thal._Thalassemia_Major"><h4>&#x003b2;-Thalassemia Major</h4><p><b>Presentation.</b> Clinical presentation of thalassemia major occurs between ages six and 24 months.</p><ul><li class="half_rhythm"><div>Affected infants fail to thrive and become progressively paler.</div></li><li class="half_rhythm"><div>Feeding problems, diarrhea, irritability, recurrent bouts of fever, and progressive enlargement of the abdomen caused by splenomegaly may occur.</div></li><li class="half_rhythm"><div>If the diagnosis of thalassemia major is established at this stage and if a regular transfusion program that maintains a minimum Hb concentration of 95 to 105 g/L is initiated, growth and development are normal at least until age ten to 11 years.</div></li></ul><p><b>Complications.</b> After age ten to 11 years, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are at risk of developing severe complications related to iron overload, depending on their compliance with chelation therapy (see <a href="#b-thal.Management">Management</a>). In individuals who have been regularly transfused, iron overload results mainly from transfusions.</p><p>Complications of iron overload include the following:</p><ul><li class="half_rhythm"><div>In children, growth restriction and failure of sexual maturation</div></li><li class="half_rhythm"><div>In adults, involvement of the heart (dilated cardiomyopathy), liver (fibrosis and cirrhosis), and endocrine glands (resulting in diabetes mellitus and insufficiency of the parathyroid, thyroid, pituitary, and, less commonly, adrenal glands)</div></li></ul><p>Other complications:</p><ul><li class="half_rhythm"><div>Hypersplenism</div></li><li class="half_rhythm"><div>Chronic hepatitis (resulting from infection with the viruses that cause hepatitis B and/or hepatitis C)</div></li><li class="half_rhythm"><div>Cirrhosis (from iron overload and chronic hepatitis)</div></li><li class="half_rhythm"><div>HIV infection</div></li><li class="half_rhythm"><div>Venous thrombosis</div></li><li class="half_rhythm"><div>Osteoporosis</div></li></ul><p>The risk for hepatocellular carcinoma is increased secondary to liver viral infection, iron overload, and longer survival [<a class="bk_pop" href="#b-thal.REF.borgnapignatti.2014.121">Borgna-Pignatti et al 2014</a>, <a class="bk_pop" href="#b-thal.REF.moukhadder.2017.751">Moukhadder et al 2017</a>].</p><p><b>Prognosis.</b> The prognosis for individuals with &#x003b2;-thalassemia major has dramatically improved over the last decades with the advent of noninvasive methods to measure organ iron before the appearance of clinical symptoms, new chelators, and increased blood safety measures.</p><p>After 2000, all of these developments have led to a significant trend in decreasing cardiac mortality, previously reported to cause 71% of the deaths in individuals with &#x003b2;-thalassemia major [<a class="bk_pop" href="#b-thal.REF.borgnapignatti.2004.114">Borgna-Pignatti et al 2004</a>, <a class="bk_pop" href="#b-thal.REF.telfer.2006.1187">Telfer et al 2006</a>, <a class="bk_pop" href="#b-thal.REF.modell.2008.42">Modell et al 2008</a>]. Recent studies show that despite geographic differences, most individuals with transfusion-dependent thalassemia have normal cardiac iron, but a significant proportion have simultaneous liver iron overload [<a class="bk_pop" href="#b-thal.REF.aydinok.2015b.244">Aydinok et al 2015b</a>].</p><p><b>Without treatment.</b> The classic clinical picture of thalassemia major is presently only seen in some developing countries, in which the resources for carrying out long-term transfusion programs are not available. The most relevant features of untreated or poorly transfused individuals:</p><ul><li class="half_rhythm"><div>Growth restriction</div></li><li class="half_rhythm"><div>Pallor</div></li><li class="half_rhythm"><div>Jaundice</div></li><li class="half_rhythm"><div>Brown pigmentation of the skin</div></li><li class="half_rhythm"><div>Poor musculature</div></li><li class="half_rhythm"><div>Genu valgum</div></li><li class="half_rhythm"><div>Hepatosplenomegaly</div></li><li class="half_rhythm"><div>Leg ulcers</div></li><li class="half_rhythm"><div>Development of masses from extramedullary hematopoiesis</div></li><li class="half_rhythm"><div>Skeletal changes that result from expansion of the bone marrow, including:</div><ul><li class="half_rhythm"><div>Deformities of the long bones of the legs</div></li><li class="half_rhythm"><div>Typical craniofacial changes (frontal bossing, malar prominence, depressed nasal bridge, tendency toward upslanted palpebral fissures, and hypertrophy of the maxillae, which tends to expose the upper teeth)</div></li><li class="half_rhythm"><div>Osteoporosis</div></li></ul></li></ul><p>Individuals who have not been regularly transfused usually die in the first two decades. Individuals who have been poorly transfused are also at risk for complications of iron overload.</p></div><div id="b-thal._Thalassemia_Intermedia"><h4>&#x003b2;-Thalassemia Intermedia</h4><p>Clinical features are pallor, jaundice, cholelithiasis, liver and spleen enlargement, moderate to severe skeletal changes, leg ulcers, extramedullary masses of hyperplastic erythroid marrow, a tendency to develop osteopenia and osteoporosis, and thrombotic complications resulting from iron accumulation and hypercoagulable state secondary to the lipid membrane composition of the abnormal red blood cells [<a class="bk_pop" href="#b-thal.REF.cappellini.2012.s20">Cappellini et al 2012</a>].</p><ul><li class="half_rhythm"><div>By definition, transfusions are not required, or only occasionally required.</div></li><li class="half_rhythm"><div>Iron overload occurs mainly from increased intestinal absorption of iron caused by deficiency of hepcidin, a 25-amino acid peptide produced by hepatocytes that plays a central role in the regulation of iron homeostasis [<a class="bk_pop" href="#b-thal.REF.nemeth.2006.727">Nemeth &#x00026; Ganz 2006</a>, <a class="bk_pop" href="#b-thal.REF.origa.2007.583">Origa et al 2007</a>]. Hepcidin deficiency is associated with ineffective erythropoiesis. The associated complications of iron overload present later, but may be as severe as those seen in individuals with thalassemia major who depend on transfusions.</div></li></ul></div></div><div id="b-thal.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>&#x003b2;&#x000ba; variants and some &#x003b2;<sup>+</sup> variants are associated with a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and result in thalassemia major in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state; however, clinical severity may be modified to thalassemia intermedia if <a href="#b-thal.Ameliorating_Genetic_Factors">ameliorating genetic factors</a> are present.</p><p>Some &#x003b2;<sup>+</sup> variants have a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>; however, the clinical severity in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state with other &#x003b2;<sup>0</sup> or &#x003b2;<sup>+</sup> variants is variable.</p><p>A few &#x003b2;+ silent variants (with a normal or borderline HbA2 and a normal MCH in the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> state) result in very mild clinical severity in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state with severe &#x003b2;<sup>0</sup> or <sup>+</sup> variants.</p><p>Common mild and silent pathogenic variants are listed in <a class="figpopup" href="/books/NBK1426/table/b-thal.T.mild_and_silent_hbb_pathogenic/?report=objectonly" target="object" rid-figpopup="figbthalTmildandsilenthbbpathogenic" rid-ob="figobbthalTmildandsilenthbbpathogenic">Table 5</a>.</p><p>Clinical presentation of compound heterozygosity for &#x003b2;-thalassemia and HbE ranges from severe to asymptomatic.</p><div id="b-thal.Ameliorating_Genetic_Factors"><h4>Ameliorating Genetic Factors</h4><p>Clinical severity of &#x003b2;<sup>+</sup>- or &#x003b2;&#x000ba;-thalassemia may be ameliorated by coinheritance of pathogenic variants in <i>HBA1</i> or <i>HBA2</i>, associated with <a href="/books/n/gene/a-thal/">&#x003b1;-thalassemia</a>, which reduce alpha globin expression, thereby decreasing the alpha/non-alpha globin chain imbalance. Due to clinical variability, <i>HBA1</i> and <i>HBA2</i> genotypes cannot be used to predict clinical outcome.</p><p>The coinheritance of some genetic determinants able to sustain a continuous production of gamma globin chains (HbF) in adult life may also reduce the extent of alpha/non-alpha globin chain imbalance:</p><ul><li class="half_rhythm"><div>The &#x003b2;-thalassemia pathogenic variants that increase gamma globin chain (HbF) output:</div><ul><li class="half_rhythm"><div>&#x003b4;&#x003b2;&#x000ba;-thalassemia caused by deletions of variable size in the <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster</div></li><li class="half_rhythm"><div>Deletions that remove only the 5' region of the <i>HBB</i> promoter, which also results in high levels of HbA<sub>2</sub></div></li></ul></li><li class="half_rhythm"><div>Co-transmission of hereditary persistence of fetal hemoglobin (HPFH), which is the result of single-nucleotide variants in the hemoglobin G&#x003b3; (<i>HBG2</i>) or hemoglobin A&#x003b3; (<i>HBG1</i>) promoter (most commonly c.-158C&#x0003e;T in <i>HBG2</i> and c.-117G&#x0003e;A in <i>HBG1</i>; see <a class="figpopup" href="/books/NBK1426/table/b-thal.T.selected_hbb_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figbthalTselectedhbbpathogenicvariant" rid-ob="figobbthalTselectedhbbpathogenicvariant">Table 4</a> and <a class="figpopup" href="/books/NBK1426/table/b-thal.T.mild_and_silent_hbb_pathogenic/?report=objectonly" target="object" rid-figpopup="figbthalTmildandsilenthbbpathogenic" rid-ob="figobbthalTmildandsilenthbbpathogenic">Table 5</a>), may result in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li><li class="half_rhythm"><div>The c.-196C&#x0003e;T <i>HBG1</i> variant <i>in cis</i> with p.Gln40Ter has been found on some Sardinian &#x003b2;-thalassemia chromosomes (Sardinian &#x003b4;&#x003b2;&#x000ba;-thalassemia).</div></li></ul><p>Other genetic loci that are not linked to the <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster and may have an ameliorating effect on clinical features of &#x003b2;-thalassemia have been suggested [<a class="bk_pop" href="#b-thal.REF.sankaran.2008.1839">Sankaran et al 2008</a>, <a class="bk_pop" href="#b-thal.REF.uda.2008.1620">Uda et al 2008</a>, <a class="bk_pop" href="#b-thal.REF.galanello.2009.3935">Galanello et al 2009</a>, <a class="bk_pop" href="#b-thal.REF.thein.2009.r216">Thein et al 2009</a>, <a class="bk_pop" href="#b-thal.REF.borg.2010.801">Borg et al 2010</a>, <a class="bk_pop" href="#b-thal.REF.satta.2011.767">Satta et al 2011</a>, <a class="bk_pop" href="#b-thal.REF.gallienne.2012.340">Gallienne et al 2012</a>].</p><p>In some instances, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> &#x003b2;-thalassemia may lead to the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of thalassemia intermedia instead of the asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> state. Known molecular mechanisms include the following:</p><ul><li class="half_rhythm"><div>Heterozygosity for pathogenic variants in <i>HBB</i> that result in hyper-unstable hemoglobins (dominant &#x003b2;-thalassemia), which precipitate in the red cell membrane together with unassembled alpha globin chains, resulting in markedly ineffective erythropoiesis. Most of these <i>HBB</i> pathogenic variants lie in the third <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> and lead to the production of a markedly unstable Hb variant often not detectable in peripheral blood.</div></li><li class="half_rhythm"><div>Double heterozygosity for typical &#x003b2;-thalassemia pathogenic variants and the triple or (less frequently) quadruple alpha <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> arrangement (&#x003b1;&#x003b1;&#x003b1;/&#x003b1;&#x003b1; or &#x003b1;&#x003b1;&#x003b1;/&#x003b1;&#x003b1;&#x003b1; or &#x003b1;&#x003b1;&#x003b1;&#x003b1;/&#x003b1;&#x003b1;) may <b>increase</b> the imbalance in the ratio of alpha/non-alpha globin chains. Duplications of the entire alpha globin gene cluster have been reported to cause thalassemia intermedia in association with the &#x003b2;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> state [<a class="bk_pop" href="#b-thal.REF.harteveld.2008.312">Harteveld et al 2008</a>, <a class="bk_pop" href="#b-thal.REF.sollaino.2009.1445">Sollaino et al 2009</a>, <a class="bk_pop" href="#b-thal.REF.origa.2014.162">Origa et al 2014</a>].</div></li></ul><p>Genetic determinants capable of sustaining continuous production of HbF in adult life outside the <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster have been mapped to <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 2p16 and chromosome 6q23 [<a class="bk_pop" href="#b-thal.REF.uda.2008.1620">Uda et al 2008</a>].</p><ul><li class="half_rhythm"><div>The 2p16 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> identified by GWAS mapped to <i>BCL11A</i> (rs11886868; c.386-24278C&#x0003e;T in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 2) and was found strongly associated with HbF levels. The c.386-24278C <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was significantly more common in <sup>0</sup> homozygotes for p.Gln40Ter with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and in patients with mild sickle cell disease [<a class="bk_pop" href="#b-thal.REF.lettre.2008.11869">Lettre et al 2008</a>, <a class="bk_pop" href="#b-thal.REF.uda.2008.1620">Uda et al 2008</a>]. The c.386-24278C&#x0003e;T <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> in young patients with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> &#x003b2;-thalassemia and sickle cell anemia may serve as a prognostic indication for the severity of the disease. Furthermore, targeted downregulation of BCL11A in patients could elevate HbF levels and thereby ameliorate the severity of these inherited anemias.</div></li><li class="half_rhythm"><div>A genetic variant associated with HbF variation was mapped to the <i>HBS1L-MYB</i> region on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 6 [<a class="bk_pop" href="#b-thal.REF.creary.2009.e4218">Creary et al 2009</a>]. Recent studies have shown that the <i>HBS1L-MYB</i> intergenic variants contain regulatory sequences controlling <i>MYB</i> expression. Coinheritance of these HPFH determinants and alpha-thalassemia contribute in the amelioration of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> &#x003b2;-thalassemia accounting for 75% of difference in clinical severity [<a class="bk_pop" href="#b-thal.REF.galanello.2009.3935">Galanello et al 2009</a>].</div></li></ul><p>Recently, it was suggested that three factors &#x02013; the type of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>HBB</i>, <i>HBA</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> defects, and fetal hemoglobin production modulators (<i>HBG2</i>:c.-158C&#x0003e;T, <i>HBS1L-MYB</i> intergenic region, and the <i>BCL11A</i>: c.386-24278G&#x0003e;A) &#x02013; combine to build a predictive score of disease severity, based on a representative cohort of 890 patients with non-transfusion-dependent and transfusion-dependent &#x003b2;-thalassemia. The effect of these loci on the transfusion-free survival probability and on the age at which the patient started regular transfusions was demonstrated [<a class="bk_pop" href="#b-thal.REF.danjou.2015.452">Danjou et al 2015</a>].</p><p><b>Other modifying factors.</b> The clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> &#x003b2;-thalassemia may also be modified by the coinheritance of secondary genetic factors mapping outside the &#x003b2;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster, which influence the complications of the thalassemia phenotype [<a class="bk_pop" href="#b-thal.REF.origa.2008.143">Origa et al 2008</a>, <a class="bk_pop" href="#b-thal.REF.origa.2009.22">Origa et al 2009</a>].</p></div></div><div id="b-thal.Nomenclature"><h3>Nomenclature</h3><p>&#x003b2;-thalassemia includes three main forms:</p><ul><li class="half_rhythm"><div>&#x003b2;-thalassemia major, also referred as "Cooley&#x02019;s anemia," "Mediterranean anemia," or "transfusion-dependent thalassemia (TDT);</div></li><li class="half_rhythm"><div>&#x003b2;-thalassemia intermedia; and</div></li><li class="half_rhythm"><div>Thalassemia minor, called "&#x003b2;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>," "&#x003b2;-thalassemia trait," or "<a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> &#x003b2;-thalassemia."</div></li></ul><p>Non-transfusion-dependent thalassemias (NTDT) is a term used to label patients who do not require lifelong regular transfusions for survival; NTDT encompasses &#x003b2;-thalassemia intermedia, hemoglobin E/&#x003b2;-thalassemia (mild and moderate forms), and &#x003b1;-thalassemia intermedia (hemoglobin H disease).</p></div><div id="b-thal.Prevalence"><h3>Prevalence</h3><p>&#x003b2;-thalassemia is prevalent in populations in the Mediterranean, the Middle East, the Transcaucasus, Central Asia, the Indian subcontinent, and the Far East. It is also common in populations of African heritage. The highest incidences are reported in Cyprus (14%), Sardinia (12%), and Southeast Asia.</p><p>The high <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> frequency of &#x003b2;-thalassemias in these regions is most likely related to selective pressure from malaria. This distribution is quite similar to that of endemic <i>Plasmodium falciparum</i> malaria. However, because of population migration and (to a limited degree) the slave trade, &#x003b2;-thalassemia is now also common in northern Europe, North and South America, the Caribbean, and Australia.</p></div></div><div id="b-thal.Genetically_Related_Allelic_Disor"><h2 id="_b-thal_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>Other phenotypes associated with pathogenic variants in <i>HBB</i> are <a href="/books/n/gene/sickle/">sickle cell disease</a> caused by A&#x0003e;T substitution at codon 6 (p.Glu6Val) (c.17A&#x0003e;T, <a href="/nuccore/NM_000518.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000518.4</a>) and other nucleotide substitutions responsible for hemoglobin variants (<a href="http://globin.cse.psu.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">globin.cse.psu.edu</a>).</p><p>Hemoglobin E (HbE), which is a thalassemic structural variant characterized by the presence of an abnormal structure as well as biosynthetic defect, should be included in this group. The nucleotide substitution at codon 26 of <i>HBB</i>, producing the HbE variant (&#x003b1;<sub>2</sub> &#x003b2;<sub>2</sub>26 E&#x0003e;K), activates a potential cryptic RNA splice region, resulting in alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> at this position. The <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state for HbE results in a mild hemolytic microcytic anemia.</p><p>The very rare, so-called dominant &#x003b2;-thalassemias or thalassemic hemoglobinopathies (OMIM <a href="https://omim.org/entry/603902" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603902</a>) result in an abnormal hyper-unstable protein product. The presence of hyper-unstable hemoglobin should be suspected in any individual with thalassemia intermedia when both parents are hematologically normal or in families with a pattern of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> transmission of the thalassemia intermedia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. <i>HBB</i> sequencing establishes the diagnosis.</p></div><div id="b-thal.Differential_Diagnosis"><h2 id="_b-thal_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>&#x003b2;-thalassemia associated with other features.</b> In rare instances the &#x003b2;-thalassemia defect does not lie in <i>HBB</i> or in the &#x003b2;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster. In instances in which the &#x003b2;-thalassemia trait is associated with other features, the molecular lesion has been found either in the gene encoding the <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> <i>TFIIH</i> (&#x003b2;-thalassemia trait associated with <a href="/books/n/gene/xp/">xeroderma pigmentosum</a> and trichothiodystrophy) or in the <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> transcription factor <i>GATA-1</i> (X-linked thrombocytopenia with thalassemia) (see <a href="/books/n/gene/gata1/"><i>GATA1</i>-Related X-Linked Cytopenia</a>) [<a class="bk_pop" href="#b-thal.REF.viprakasit.2001.2797">Viprakasit et al 2001</a>, <a class="bk_pop" href="#b-thal.REF.freson.2002.147">Freson et al 2002</a>].</p><p>Few conditions share similarities with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> &#x003b2;-thalassemia.</p><ul><li class="half_rhythm"><div>The genetically determined sideroblastic anemias are easily differentiated because of ring sideroblasts in the bone marrow and variably elevated serum concentration of erythrocyte protoporphyrin. Most sideroblastic anemia is associated with defects in the heme biosynthetic pathway, especially &#x003b4;-aminolevulinic acid synthase (see also <a href="/books/n/gene/sider-anemia/">X-Linked Sideroblastic Anemia and Ataxia</a>).</div></li><li class="half_rhythm"><div>Congenital dyserythropoietic anemias do not have high HbF and do have other distinctive features, such as multinuclearity of the red blood cell precursors (see <a href="/books/n/gene/cda1/">Congenital Dyserythropoietic Anemia Type I</a>).</div></li><li class="half_rhythm"><div>A few acquired conditions associated with high HbF (juvenile chronic myeloid leukemia, aplastic anemia) may be mistaken for &#x003b2;-thalassemia, even though they have very characteristic hematologic features.</div></li></ul></div><div id="b-thal.Management"><h2 id="_b-thal_Management_">Management</h2><div id="b-thal.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with &#x003b2;-thalassemia, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div class="half_rhythm">The initial step following diagnosis of &#x003b2;-thalassemia in an individual is to distinguish between those who have thalassemia intermedia (requiring intermittent transfusions on an as-needed basis) from those with thalassemia major (who need a regular transfusion program). See <a href="#b-thal.Establishing_the_Diagnosis">Establishing the Diagnosis</a>.</div><div class="half_rhythm">The following should be included in the investigations when deciding whom to transfuse:</div><ul><li class="half_rhythm"><div>Confirmed diagnosis of thalassemia; and</div></li><li class="half_rhythm"><div>Hemoglobin level &#x0003c;7 g/dL on two occasions, more than two weeks apart (excluding all other contributory causes, such as infections), or presence of the following features, regardless of hemoglobin level:</div><ul><li class="half_rhythm"><div>Facial changes</div></li><li class="half_rhythm"><div>Poor growth</div></li><li class="half_rhythm"><div>Bony fractures</div></li><li class="half_rhythm"><div>Clinically significant extramedullary hematopoiesis</div></li></ul></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Consultation with a clinical geneticist and/or genetic counselor is appropriate.</div></li></ul></div><div id="b-thal.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Comprehensive reviews of the management of thalassemia major and thalassemia intermedia have been published by the Thalassemia International Federation [<a class="bk_pop" href="#b-thal.REF.taher.2013">Taher et al 2013</a>, <a class="bk_pop" href="#b-thal.REF.cappellini.2014">Cappellini et al 2014</a>] and are available at the TIF <a href="http://thalassaemia.org.cy/publications/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">website</a>.</p><p><b>Thalassemia major.</b> Regular transfusions correct the anemia, suppress erythropoiesis, and inhibit increased gastrointestinal absorption of iron.</p><ul><li class="half_rhythm"><div>Before starting the transfusions, the following are absolutely necessary:</div><ul><li class="half_rhythm"><div>Hepatitis B vaccination</div></li><li class="half_rhythm"><div>Extensive red blood cell antigen typing, including Rh, Kell, Kidd, and Duffy and serum immunoglobulin determination &#x02013; the latter of which detects individuals with IgA deficiency, who need special (repeatedly washed) blood unit preparation before each transfusion</div></li></ul></li><li class="half_rhythm"><div>The transfusion regimen is designed to obtain a pre-transfusion Hb concentration of 95-100 g/L.</div></li><li class="half_rhythm"><div>Transfusions are usually given every two to three weeks.</div></li></ul><p><b>Thalassemia intermedia.</b> Treatment of individuals with thalassemia intermedia is symptomatic and based on splenectomy and folic acid supplementation.</p><ul><li class="half_rhythm"><div class="half_rhythm">Treatment of extramedullary erythropoietic masses is based on radiotherapy, transfusions, or, in selected cases, hydroxyurea (with a protocol similar to that used for <a href="/books/n/gene/sickle/">sickle cell disease</a>).</div><div class="half_rhythm">Hydroxyurea also increases globin gamma chains and may have other undefined effects.</div></li><li class="half_rhythm"><div class="half_rhythm">Individuals with thalassemia intermedia may develop iron overload from increased gastrointestinal absorption of iron or from occasional transfusions; chelation therapy with deferasirox has been demonstrated to be safe and effective in persons age ten years or older with a liver iron concentration &#x02265;5 mg Fe/g dry weight or serum ferritin &#x02265;800 ng/mL (thresholds after which the risk of serious iron-related morbidity is increased) [<a class="bk_pop" href="#b-thal.REF.taher.2012.970">Taher et al 2012</a>].</div></li></ul><p><b>Bone marrow transplantation</b></p><ul><li class="half_rhythm"><div>Bone marrow transplantation (BMT) from an HLA-identical sib represents an alternative to traditional transfusion and chelation therapy. If BMT is successful, iron overload may be reduced by repeated phlebotomy, thus eliminating the need for iron chelation.</div></li><li class="half_rhythm"><div>The outcome of BMT is related to the pretransplantation clinical conditions, specifically the presence of hepatomegaly, extent of liver fibrosis, and magnitude of iron accumulation. In children who lack the above risk factors, disease-free survival is higher than 90%. Adults with beta-thalassemia are at increased risk for transplant-related toxicity due to an advanced phase of the disease and have a two-year overall survival of 80% and a two-year event-free survival of 76% with current treatment protocol [<a class="bk_pop" href="#b-thal.REF.baronciani.2016.536">Baronciani et al 2016</a>].</div></li><li class="half_rhythm"><div>BMT from unrelated donors has been carried out on a limited number of individuals with &#x003b2;-thalassemia. Provided that selection of the donor is based on stringent criteria of HLA compatibility and that individuals have limited iron overload, results are comparable to those obtained when the donor is a compatible sib [<a class="bk_pop" href="#b-thal.REF.la_nasa.2005.186">La Nasa et al 2005</a>, <a class="bk_pop" href="#b-thal.REF.gaziev.2013.2751">Gaziev et al 2013</a>].</div></li><li class="half_rhythm"><div>Severe acute graft-vs-host disease (GVHD) may occur in 9% of individuals, with a lower risk observed in those with an HLA-matched sib donor.</div></li><li class="half_rhythm"><div>Affected individuals without matched donors could also benefit from haploidentical mother-to-child transplantation, the results of which appear encouraging [<a class="bk_pop" href="#b-thal.REF.sodani.2011.e13">Sodani et al 2011</a>, <a class="bk_pop" href="#b-thal.REF.anurathapan.2016.813">Anurathapan et al 2016</a>].</div></li></ul><p><b>Cord blood transplantation.</b> Cord blood transplantation from a related donor offers a good probability of a successful cure and is associated with a low risk for GVHD [<a class="bk_pop" href="#b-thal.REF.pinto.2008.309">Pinto &#x00026; Roberts 2008</a>]. For couples who have already had a child with thalassemia and who undertake <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> in a subsequent pregnancy, prenatal identification of HLA compatibility between the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child and an unaffected fetus allows collection of placental blood at delivery and the option of cord blood transplantation to cure the affected child [<a class="bk_pop" href="#b-thal.REF.orofino.2003.41">Orofino et al 2003</a>]. Alternatively, in case of an affected fetus and a previous unaffected child, the couple may decide to continue the pregnancy and pursue BMT later, using the unaffected child as the donor.</p><p>Unrelated cord blood transplantation has been explored as an alternative option for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals without a suitable HLA-matched unrelated adult donor. However, this strategy may be limited by less-than-adequate cell dose and higher rates of primary graft failure. One potential strategy may be the use of two cord blood units in order to achieve the desired cell dose, as has been done in individuals with malignancy &#x02013; although this approach may be associated with a higher rate of acute GVHD, which may add to the burden of morbidity and mortality for this population.</p><p>For these reasons, unrelated cord blood transplantation would appear to be a suboptimal strategy for individuals with thalassemia [<a class="bk_pop" href="#b-thal.REF.ruggeri.2011.1375">Ruggeri et al 2011</a>]. However, others have found the outcome of unrelated cord blood transplantation to be more favorable. <a class="bk_pop" href="#b-thal.REF.jaing.2012.33">Jaing et al [2012]</a> reported an overall survival of 88% and a thalassemia-free survival of 74% in 35 individuals with &#x003b2;-thalassemia.</p></div><div id="b-thal.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p>Early detection of anemia, the primary manifestation of the disease, allows early appropriate treatment and monitoring.</p></div><div id="b-thal.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><div id="b-thal.Transfusional_Iron_Overload"><h4>Transfusional Iron Overload</h4><p>The most common secondary complications are those related to transfusional iron overload, which can be prevented by adequate iron chelation.</p><p><b>Assessment of iron overload</b></p><ul><li class="half_rhythm"><div><b>Serum ferritin concentration.</b> In clinical practice, the effectiveness of chelators is monitored by routine determination of serum ferritin concentration. However, serum ferritin concentration is not always reliable for evaluating iron burden because it is influenced by other factors, the most important being the extent of liver damage.</div></li><li class="half_rhythm"><div><b>Liver biopsy.</b> Determination of liver iron concentration in a liver biopsy specimen shows a high correlation with total body iron accumulation and is the gold standard for evaluation of liver iron overload. However, (1) liver biopsy is an invasive technique involving the possibility (though low) of complications; (2) liver iron content can be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by hepatic fibrosis, which commonly occurs in individuals with iron overload and hepatitis C virus infection; and (3) irregular iron distribution in the liver can lead to false negative results [<a class="bk_pop" href="#b-thal.REF.clark.2003.572">Clark et al 2003</a>].</div></li><li class="half_rhythm"><div><b>Magnetic biosusceptometry (SQUID),</b> which gives a reliable measurement of hepatic iron concentration, is another option [<a class="bk_pop" href="#b-thal.REF.fischer.2003.938">Fischer et al 2003</a>]; however, magnetic susceptometry is presently available only in a limited number of centers worldwide.</div></li><li class="half_rhythm"><div><b>MRI techniques</b> for assessing iron loading in the liver and heart are commonly used [<a class="bk_pop" href="#b-thal.REF.pennell.2005.373">Pennell 2005</a>, <a class="bk_pop" href="#b-thal.REF.wood.2008.s14">Wood 2008</a>]. T<sub>2</sub> and T<sub>2</sub>* parameters have been validated for liver iron concentration. Cardiac T<sub>2</sub>* is reproducible, is applicable between different scanners, correlates with cardiac function, and relates to tissue iron concentration [<a class="bk_pop" href="#b-thal.REF.pennell.2005.373">Pennell 2005</a>, <a class="bk_pop" href="#b-thal.REF.wood.2008.s14">Wood 2008</a>]. Clinical utility of T<sub>2</sub>* in monitoring individuals with siderotic cardiomyopathy has been demonstrated. In one study, 12 human hearts from transfusion-dependent <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals after either death or transplantation for end-stage heart failure underwent cardiovascular magnetic resonance R<sub>2</sub>* (the reciprocal of T<sub>2</sub>*) measurement. Tissue iron concentration was measured in multiple samples of each heart with inductively coupled plasma atomic emission spectroscopy, providing calibration in humans for cardiovascular magnetic resonance R<sub>2</sub>* against myocardial iron concentration and detailing the iron distribution throughout the heart in iron overload [<a class="bk_pop" href="#b-thal.REF.carpenter.2011.1519">Carpenter et al 2011</a>].</div></li></ul><p><b>Chelation therapy</b></p><ul><li class="half_rhythm"><div><b>Desferrioxamine B (DFO).</b> The first chelator introduced clinically was desferrioxamine B (DFO) administered five to seven days a week by 12-hour continuous subcutaneous infusion via a portable pump. Recommended dosage depends on the individual's age and the serum ferritin concentration. Young children start with 20-30 mg/kg/day, increasing up to 40 mg/kg/day after age five to six years. The maximum dose is 50 mg/kg/day after growth is completed. The dose may be reduced if serum ferritin concentration is low. By maintaining the total body iron stores below critical values (i.e., hepatic iron concentration &#x0003c;7.0 mg per gram of dry weight liver tissue), desferrioxamine B therapy prevents the secondary effects of iron overload, resulting in a consistent decrease in morbidity and mortality [<a class="bk_pop" href="#b-thal.REF.borgnapignatti.2004.114">Borgna-Pignatti et al 2004</a>].</div><ul><li class="half_rhythm"><div>Ascorbate repletion (daily dose &#x02264;100-150 mg) increases the amount of iron removed after DFO administration.</div></li><li class="half_rhythm"><div>Side effects of DFO chelation therapy are more common in the presence of relatively low iron burden and include ocular and auditory toxicity, growth restriction, and, rarely, renal impairment and interstitial pneumonitis. DFO administration also increases susceptibility to <i>Yersinia</i> infections. The major drawback of DFO chelation therapy is low compliance resulting from complications of administration.</div></li></ul></li><li class="half_rhythm"><div><b>Deferiprone,</b> a bidentated oral chelator, is administered in a dose of 75-100 mg/kg/day. The main side effects of deferiprone therapy include arthropathy, gastrointestinal symptoms, and, above all, neutropenia and agranulocytosis [<a class="bk_pop" href="#b-thal.REF.galanello.2009.155">Galanello &#x00026; Campus 2009</a>] that demand close monitoring. The effect of deferiprone on liver iron concentration may vary among the individuals treated. However, results from independent studies suggest that deferiprone is more cardioprotective than desferrioxamine: compared to those being treated with DFO, individuals being treated with deferiprone have better myocardial MRI pattern and less probability of developing (or worsening pre-existing) cardiac disease [<a class="bk_pop" href="#b-thal.REF.anderson.2002.516">Anderson et al 2002</a>, <a class="bk_pop" href="#b-thal.REF.piga.2003.489">Piga et al 2003</a>]. These retrospective observations have been confirmed in a prospective study [<a class="bk_pop" href="#b-thal.REF.pennell.2006.3738">Pennell et al 2006</a>].</div></li><li class="half_rhythm"><div><b>Deferasirox</b> was developed as a once-daily oral monotherapy for the treatment of transfusional iron overload. It is effective in adults and children and has a defined safety profile that is clinically manageable with appropriate monitoring. The most common treatment-related adverse events are gastrointestinal disorders, skin rash, and a mild, non-progressive increase in serum creatinine concentration [<a class="bk_pop" href="#b-thal.REF.cappellini.2008.s35">Cappellini 2008</a>]. Cases of renal failure, hepatic failure, cytopenias, and gastrointestinal hemorrhage have been reported in the post-marketing phase. Provided adequate doses are given, there is a good response to deferasirox across the full range of baseline liver iron concentration values. Prospective data demonstrate the efficacy of deferasirox in improving myocardial T<sub>2</sub>* and in maintaining a normal left ventricle ejection fraction [<a class="bk_pop" href="#b-thal.REF.pennell.2012.842">Pennell et al 2012</a>, <a class="bk_pop" href="#b-thal.REF.pennell.2014.1447">Pennell et al 2014</a>]. Deferasirox has not been evaluated in formal trials for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with symptomatic heart failure or low left-ventricle ejection fraction.</div></li><li class="half_rhythm"><div><b>Combination therapies.</b> Strategies of chelation using a combination of desferrioxamine and deferiprone have been effective in individuals with severe iron overload. Retrospective, prospective, and randomized clinical studies have shown that combined iron chelation with desferrioxamine and deferiprone rapidly reduces myocardial siderosis, improves cardiac and endocrine function, reduces liver iron and serum ferritin concentration, reduces cardiac mortality, and improves survival; toxicity is manageable [<a class="bk_pop" href="#b-thal.REF.tanner.2007.1876">Tanner et al 2007</a>, <a class="bk_pop" href="#b-thal.REF.galanello.2010.79">Galanello et al 2010</a>].</div></li></ul><p>An open-label single-arm prospective Phase II study evaluated combination deferasirox-desferrioxamine in patients with severe transfusional myocardial siderosis followed by optional switch to deferasirox (DFX) monotherapy when achieving mT<sub>2</sub>* &#x0003e;10 ms, demonstrating that this association is able to rapidly decrease liver iron accumulation in heavily loaded patients and to lower myocardial overload in one third of them [<a class="bk_pop" href="#b-thal.REF.aydinok.2015a.3868">Aydinok et al 2015a</a>].</p><p>Preliminary studies using in combination the two oral chelators deferasirox and deferiprone appear to be encouraging [<a class="bk_pop" href="#b-thal.REF.berdoukas.2010.1177">Berdoukas et al 2010</a>, <a class="bk_pop" href="#b-thal.REF.farmaki.2011.33">Farmaki et al 2011</a>, <a class="bk_pop" href="#b-thal.REF.voskaridou.2011.654">Voskaridou et al 2011</a>, <a class="bk_pop" href="#b-thal.REF.elalfy.2015.411">Elalfy et al 2015</a>].</p></div><div id="b-thal.Cardiac_Disease"><h4>Cardiac Disease</h4><p>Particular attention has been directed to the early diagnosis and treatment of cardiac disease because of its critical role in determining the prognosis of individuals with &#x003b2;-thalassemia. Assessment of myocardial siderosis by MRI techniques and monitoring of cardiac function combined with intensification of iron chelation can result in excellent long-term prognoses [<a class="bk_pop" href="#b-thal.REF.wood.2008.s14">Wood 2008</a>, <a class="bk_pop" href="#b-thal.REF.kirk.2009.1961">Kirk et al 2009</a>, <a class="bk_pop" href="#b-thal.REF.chouliaras.2011.56">Chouliaras et al 2011</a>].</p></div><div id="b-thal.Osteoporosis"><h4>Osteoporosis</h4><p>Osteoporosis is a common complication in adults with thalassemia major or thalassemia intermedia [<a class="bk_pop" href="#b-thal.REF.voskaridou.2008.86">Voskaridou &#x00026; Terpos 2008</a>]. Its origin is <a class="def" href="/books/n/gene/glossary/def-item/multifactorial/">multifactorial</a>, making it difficult to manage. Treatment involves appropriate hormonal replacement, an effective regimen of transfusion and iron chelation, vitamin D administration, and regular physical activity. Sufficient evidence exists to support the use of bisphosphonates in the management of thalassemia-associated osteoporosis (to prevent bone loss and improve the bone mineral density). Further research is warranted to establish their anti-fracture efficacy and long-term safety [<a class="bk_pop" href="#b-thal.REF.giusti.2014.606">Giusti 2014</a>]. Denosumab and strontium ranelate have each been evaluated in only a single study, while there are no data on the effects of anabolic agents [<a class="bk_pop" href="#b-thal.REF.chavassieux.2014.618">Chavassieux et al 2014</a>, <a class="bk_pop" href="#b-thal.REF.yassin.2014.546">Yassin et al 2014</a>]. However, since the origin of bone disease in thalassemia major is multifactorial and some of the underlying pathogenic mechanisms are still unclear, further research in this field is needed to allow for the design of optimal therapeutic measures [<a class="bk_pop" href="#b-thal.REF.skordis.2011.300">Skordis &#x00026; Toumba 2011</a>, <a class="bk_pop" href="#b-thal.REF.dede.2016.3409">Dede et al 2016</a>].</p></div></div><div id="b-thal.Surveillance"><h3>Surveillance</h3><p>A general timetable for clinical and laboratory evaluation in thalassemia major has been provided by the Thalassemia International Federation [<a class="bk_pop" href="#b-thal.REF.cappellini.2014">Cappellini et al 2014</a>] and is available at the TIF <a href="http://thalassaemia.org.cy/publications/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">website</a>.</p><p>For individuals with thalassemia major, follow up to monitor the effectiveness of transfusion therapy and chelation therapy and their side effects includes the following:</p><ul><li class="half_rhythm"><div>Monthly physical examination by a physician familiar with the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and the disease</div></li><li class="half_rhythm"><div>Every three months: assessment of liver function tests (serum concentration of ALT), determination of serum ferritin concentration, and assessment of growth and development (during childhood)</div></li><li class="half_rhythm"><div>Annual</div><ul><li class="half_rhythm"><div>Ophthalmologic and audiologic examinations</div></li><li class="half_rhythm"><div>Complete cardiac evaluation, and evaluation of thyroid, endocrine pancreas, parathyroid, adrenal, and pituitary function</div></li><li class="half_rhythm"><div>Liver ultrasound evaluation and determination of serum alpha-fetoprotein concentration in adults with hepatitis C and iron overload for early detection of hepatocarcinoma</div></li><li class="half_rhythm"><div>Bone densitometry to assess for osteoporosis in the adult</div></li><li class="half_rhythm"><div>Liver and myocardial MRI</div></li></ul></li><li class="half_rhythm"><div>Regular gallbladder echography for early detection of cholelithiasis [<a class="bk_pop" href="#b-thal.REF.origa.2009.22">Origa et al 2009</a>], particularly in individuals with the Gilbert syndrome <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> (i.e., presence of the (TA)<sub>7</sub>/(TA)<sub>7</sub> motif in the <i>UGT1A</i> promoter)</div></li><li class="half_rhythm"><div>In patients on deferasirox: monitoring of serum creatinine, creatinine clearance, and/or plasma cystatin C levels prior to therapy, weekly in the first month after initiation or modification of therapy, and monthly thereafter. Hepatic function should be checked before the initiation of treatment, every two weeks during the first month, and monthly thereafter in these patients.</div></li><li class="half_rhythm"><div>Monitoring of patient's neutrophil count every week and in case of infection in patients on deferiprone</div></li></ul></div><div id="b-thal.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Alcohol consumption, which in individuals with liver disease has a synergistic effect with iron-induced liver damage</div></li><li class="half_rhythm"><div>Iron-containing preparations</div></li></ul></div><div id="b-thal.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual as early as possible. Early detection of anemia, the primary manifestation of &#x003b2;-thalassemia, allows prompt, appropriate treatment and monitoring.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known</div></li><li class="half_rhythm"><div>Hematologic testing if the pathogenic variants in the family are not known</div></li></ul><p>See <a href="#b-thal.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="b-thal.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Provided that a multidisciplinary team is available, pregnancy is possible and safe, and usually has a favorable outcome in women with &#x003b2;-thalassemia. An increasing number of women with thalassemia major and thalassemia intermedia may, therefore, have children. While hypogonadotropic hypogonadism remains a common condition in thalassemia major, gonadal function is usually intact and fertility is usually retrievable following a closely monitored stimulation therapy.</p><p>Although larger and more detailed studies are needed, an increased risk for certain complications cannot yet be excluded. For example, women with thalassemia intermedia who had never previously received a blood transfusion or who had received a minimal quantity of blood are reported to be at risk for severe alloimmune anemia if blood transfusions are required during pregnancy [<a class="bk_pop" href="#b-thal.REF.origa.2010.376">Origa et al 2010</a>].</p></div><div id="b-thal.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Several studies in Hbb(th3/+) mice, which serve as a model of untransfused &#x003b2;-thalassemia, showed that the use of <b>minihepcidins</b> (small drug-like hepcidin agonists) ameliorates ineffective erythropoiesis, anemia, and iron overload when used either alone for prevention or possibly as adjunctive therapy with phlebotomy or chelation [<a class="bk_pop" href="#b-thal.REF.ramos.2012.3829">Ramos et al 2012</a>, <a class="bk_pop" href="#b-thal.REF.casu.2016.265">Casu et al 2016</a>]. The first clinical trials are expected soon.</p><p>The efficacy of <b>hydroxyurea treatment</b> in individuals with thalassemia is still unclear. Hydroxyurea is used in persons with thalassemia intermedia to reduce extramedullary masses, to increase hemoglobin levels, and, in some cases, to improve leg ulcers [<a class="bk_pop" href="#b-thal.REF.levin.2011.316">Levin &#x00026; Koren 2011</a>]. Hydroxyurea prevents hemolysis and hypercoagulability by modifying the defective hemoglobin synthesis and reducing thrombocytosis. A retrospective study found no pulmonary hypertension in 50 individuals with thalassemia intermedia treated with hydroxyurea for seven years [<a class="bk_pop" href="#b-thal.REF.karimi.2009.213">Karimi et al 2009</a>, <a class="bk_pop" href="#b-thal.REF.taher.2010.1886">Taher et al 2010</a>]. A good response, correlated with particular polymorphisms in the beta-globin cluster (i.e., C&#x0003e;T at -158 G gamma), has been reported in individuals with transfusion dependence [<a class="bk_pop" href="#b-thal.REF.bradai.2003.1529">Bradai et al 2003</a>, <a class="bk_pop" href="#b-thal.REF.yavarian.2004.1172">Yavarian et al 2004</a>]. However, controlled and randomized studies are warranted to establish the role of hydroxyurea in the management of thalassemia syndromes.</p><p><b>Modulators of erythropoiesis,</b> such as TGF-&#x003b2;-like molecules or inhibitors of JAK2, could soon revolutionize the treatment of &#x003b2;-thalassemia and related disorders.</p><ul><li class="half_rhythm"><div>Activins, members of the TGF-&#x003b2; family signaling, are key regulators of human hematopoiesis, modulating various cellular responses such as proliferation, differentiation, migration, and apoptosis. Modified activin type II receptors inhibiting signaling induced by some members of the TGF-&#x003b2; superfamily promote maturation of terminally differentiating erythroblasts. In thalassemic mice (<i>Hbb</i><sup>th1/th1</sup>), they ameliorate hematologic parameters as well as comorbidities that develop as a consequence of the erythroid hyperplasia [<a class="bk_pop" href="#b-thal.REF.dussiot.2014.398">Dussiot et al 2014</a>, <a class="bk_pop" href="#b-thal.REF.suragani.2014.3864">Suragani et al 2014</a>]. Ongoing clinical studies are evaluating their role in reducing transfusion burden in thalassemia major and raising hemoglobin concentration in thalassemia intermedia.</div></li><li class="half_rhythm"><div>The discovery that JAK2 plays an important role in the progression and exacerbation of ineffective erythropoiesis suggests that drugs inhibiting JAK2 activity could mitigate ineffective erythropoiesis and reverse splenomegaly. In fact, in preclinical studies it has been shown that a JAK2 inhibitor dramatically decreased the spleen size and modulated the ineffective erythropoiesis [<a class="bk_pop" href="#b-thal.REF.breda.2014.375">Breda &#x00026; Rivella 2014</a>]. A JAK2 inhibitor, ruxolitinib, has been tested to limit stress erythropoiesis in a Phase II clinical trial.</div></li></ul><p>The possibility of <b>correction of the molecular defect</b> in hematopoietic stem cells by transfer of a normal <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> via a suitable vector or by homologous <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> is being actively investigated. The most promising results in the mouse model have been obtained with lentiviral vectors [<a class="bk_pop" href="#b-thal.REF.persons.2009.690">Persons 2009</a>].</p><p>Several clinical trials of <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> for &#x003b2;-TM are ongoing in France, Italy, and the United States [<a class="bk_pop" href="#b-thal.REF.ferrari.2017.835">Ferrari et al 2017</a>]. One individual with transfusion-dependent HbE/&#x003b2;-thalassemia treated in France exhibited a therapeutic effect after transplantation with autologous CD34+ cells genetically modified with a &#x003b2;-globin lentiviral vector and had not required blood transfusions as of four years after the transplantation [<a class="bk_pop" href="#b-thal.REF.cavazzanacalvo.2010.318">Cavazzana-Calvo et al 2010</a>]. Very encouraging preliminary data on individuals with HbE/&#x003b2;-thalassemia and <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> &#x003b2;-thalassemia transplanted with autologous CD34+ cells transduced with a replication-defective, self-<a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> lentiviral vector containing an engineered HBB (&#x003b2;A-T87Q) were recently reported by the same group [<a class="bk_pop" href="#b-thal.REF.negre.2016.148">Negre et al 2016</a>].</p><p>Other approaches being investigated for <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> of the &#x003b2;-hemoglobinopathies include pharmacologic or genetic induction of &#x003b3;-globin production through interference with the BCL11A pathway or disruption of the <i>BCL11A</i> erythroid enhancer by CRISPR/CAS9 technology as well as zinc finger or transcription activator&#x02013;like effector nuclease, and even using genome editing in attempts at repairing the defective HBB in hematopoietic stem cells [<a class="bk_pop" href="#b-thal.REF.cottle.2016.993">Cottle et al 2016</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="b-thal.Genetic_Counseling"><h2 id="_b-thal_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="b-thal.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>The &#x003b2;-thalassemias are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="b-thal.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes and therefore carry a single copy of an <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are clinically asymptomatic but occasionally slightly anemic. Carriers are often referred to as having thalassemia minor (or &#x003b2;-thalassemia minor).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being a clinically asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are clinically asymptomatic but occasionally slightly anemic. Carriers are often referred to as having thalassemia minor (or &#x003b2;-thalassemia minor).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with &#x003b2;-thalassemia are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>HBB</i>.</div></li><li class="half_rhythm"><div>Because of the high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for &#x003b2;-thalassemia in certain populations (see <a href="#b-thal.Prevalence">Prevalence</a>), the offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and a reproductive partner from one of the high-prevalence areas are at increased risk for &#x003b2;-thalassemia.</div></li><li class="half_rhythm"><div>Given the high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for &#x003b2;-thalassemia in these populations, it is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> to the partner of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with &#x003b2;-thalassemia.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="b-thal.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives can be done by hematologic or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>Individuals who should be considered for <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> detection:</p><ul><li class="half_rhythm"><div>Family members</div></li><li class="half_rhythm"><div>Gamete donors</div></li><li class="half_rhythm"><div>Members of at-risk ethnic groups (see <a class="figpopup" href="/books/NBK1426/table/b-thal.T.selected_hbb_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figbthalTselectedhbbpathogenicvariant" rid-ob="figobbthalTselectedhbbpathogenicvariant">Table 4</a>)</div></li></ul><p><b>Hematologic testing.</b> The <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> state is often referred to as &#x003b2;-thalassemia minor. Carriers are often identified by analysis of red blood cell indices (<a class="figpopup" href="/books/NBK1426/table/b-thal.T.red_blood_cell_indices_in_betat/?report=objectonly" target="object" rid-figpopup="figbthalTredbloodcellindicesinbetat" rid-ob="figobbthalTredbloodcellindicesinbetat">Table 1</a>), which shows microcytosis (low MCV) and reduced content of Hb per red cell (low MCH), and by quantitative Hb analysis (<a class="figpopup" href="/books/NBK1426/table/b-thal.T.hemoglobin_patterns_in_betathal/?report=objectonly" target="object" rid-figpopup="figbthalThemoglobinpatternsinbetathal" rid-ob="figobbthalThemoglobinpatternsinbetathal">Table 2</a>), which displays HbA<sub>2</sub> greater than 3.5%.</p><p><b>Pitfalls in <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> identification</b> by hematologic testing:</p><ul><li class="half_rhythm"><div>Coinheritance of &#x003b1;-thalassemia, which may normalize the red blood cell indices. However, in &#x003b1;/&#x003b2; double heterozygotes, the HbA<sub>2</sub> concentration remains in the &#x003b2;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> range and thus is of diagnostic value.</div></li><li class="half_rhythm"><div>Coinheritance of &#x003b4;-thalassemia, which reduces to normal the increased HbA<sub>2</sub> levels typical of the &#x003b2;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> state. Double heterozygosity for &#x003b4;- and &#x003b2;-thalassemia can be distinguished from the most common &#x003b1;-thalassemia carrier state by globin chain synthesis or globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> analysis.</div></li><li class="half_rhythm"><div>Confusion of &#x003b1;-thalassemia carriers with &#x003b2;-thalassemia carriers, resulting from microcytosis and hypochromia. However, &#x003b1;-thalassemia carriers are easily distinguished by normal HbA<sub>2</sub> levels (see <a href="/books/n/gene/a-thal/">Alpha-Thalassemia</a>).</div></li><li class="half_rhythm"><div>Silent <i>HBB</i> variants &#x02013; very mild pathogenic variants associated with consistent residual output of hemoglobin beta chains and with normal RBC indices and normal or borderline HbA<sub>2</sub>. However, homozygosity for silent pathogenic variants or compound heterozygosity for a silent <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and a typical <i>HBB</i> pathogenic variant result in mild non-transfusion-dependent forms of &#x003b2;-thalassemia.</div></li></ul><p><b>Molecular genetic testing.</b> When the hematologic analysis is abnormal, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>HBB</i> may be performed to identify the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, including mild and silent &#x003b2;-thalassemia pathogenic variants.</p></div><div id="b-thal.Population_Screening"><h3>Population Screening</h3><p><b>Individuals at increased risk.</b> Because of the high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for <i>HBB</i> pathogenic variants in certain populations and the availability of <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>, population screening is ongoing in several at-risk populations in the Mediterranean [<a class="bk_pop" href="#b-thal.REF.angastiniotis.2013">Angastiniotis et al 2013</a>]. Carrier testing relies on hematologic analysis. When the hematologic analysis indicates a &#x003b2;-thalassemia carrier state, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>HBB</i> can be performed to identify a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. If both partners of a couple have the <i>HBB</i> pathogenic variant, each of their offspring has a 1/4 risk of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Through genetic counseling and the option of prenatal testing, such a couple can opt to bring to term only those pregnancies in which the fetus is unaffected.</p></div><div id="b-thal.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#b-thal.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>A thorough overview of the issues involved in thalassemia prevention is provided in <i>Prevention of Thalassaemias and other Haemoglobin Disorders</i>
<a href="http://ukts.org/pdfs/tifpubs/preventionv1.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Volume 1</a> [<a class="bk_pop" href="#b-thal.REF.angastiniotis.2013">Angastiniotis et al 2013</a>] and <a href="http://ukts.org/pdfs/tifpubs/preventionv2.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Volume 2</a> [<a class="bk_pop" href="#b-thal.REF.harteveld.2012">Harteveld et al 2012</a>].</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="b-thal.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once both <i>HBB</i> pathogenic variants have been identified in the couple at risk, prenatal testing and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Prenatal diagnosis is available not only in cases of high-risk pregnancies but also in indeterminate-risk pregnancies.</p><p>An indeterminate-risk pregnancy is one in which:</p><ul><li class="half_rhythm"><div>One parent is a definite <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> and the other parent has a &#x003b2;-thalassemia-like hematologic picture, but no <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>;</div></li><li class="half_rhythm"><div>The mother is a known <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> and the father is unknown or unavailable for testing, especially if the father belongs to a population at risk.</div></li></ul><p>Options for noninvasive <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>:</p><ul><li class="half_rhythm"><div><b>Analysis of fetal cells in maternal blood.</b> Prenatal diagnosis by analysis of fetal cells in maternal blood is being investigated [<a class="bk_pop" href="#b-thal.REF.kolialexi.2007.1228">Kolialexi et al 2007</a>]. However, the rarity of fetal erythroblasts in the maternal circulation limits the practicability of this approach [<a class="bk_pop" href="#b-thal.REF.traegersynodinos.2011.299">Traeger-Synodinos et al 2011</a>, <a class="bk_pop" href="#b-thal.REF.allen.2017.73">Allen et al 2017</a>].</div></li><li class="half_rhythm"><div><b>Analysis of fetal DNA in maternal plasma</b> for the presence of the father's <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may lead to prenatal exclusion of <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> &#x003b2;-thalassemia. This testing is being investigated with promising results [<a class="bk_pop" href="#b-thal.REF.tungwiwat.2007.319">Tungwiwat et al 2007</a>, <a class="bk_pop" href="#b-thal.REF.lun.2008.19920">Lun et al 2008</a>, <a class="bk_pop" href="#b-thal.REF.hahn.2011.e16">Hahn et al 2011</a>, <a class="bk_pop" href="#b-thal.REF.lam.2012.1467">Lam et al 2012</a>, <a class="bk_pop" href="#b-thal.REF.phylipsen.2012.578">Phylipsen et al 2012</a>, <a class="bk_pop" href="#b-thal.REF.xiong.2015.258">Xiong et al 2015</a>, <a class="bk_pop" href="#b-thal.REF.zafari.2016.1341">Zafari et al 2016</a>].</div></li></ul><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="b-thal.Resources"><h2 id="_b-thal_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Cooley's Anemia Foundation</b></div><div>330 Seventh Avenue</div><div>#200</div><div>New York NY 10001</div><div><b>Phone:</b> 212-279-8090</div><div><b>Fax:</b> 212-279-5999</div><div><a href="https://www.thalassemia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Thalassemia</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Beta-thalassemia&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Beta-thalassemia</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22200/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Thalassemia</a></div></li><li class="half_rhythm"><div><b>Thalassaemia International Federation (TIF)</b></div><div>PO Box 28807</div><div> Nicosia 2083</div><div>Cyprus</div><div><b>Phone:</b> +357 22 319129</div><div><b>Fax:</b> +357 22 314552</div><div><b>Email:</b> thalassaemia@cytanet.com.cy</div><div><a href="http://www.thalassaemia.org.cy" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.thalassaemia.org.cy</a></div></li><li class="half_rhythm"><div><b>National Haemoglobinopathy Registry</b></div><div>MDSAS NHR Administrator</div><div>5 Union Street</div><div>City View House</div><div> Manchester M12 4JD</div><div>United Kingdom</div><div><b>Phone:</b> 0161 277 7917</div><div><b>Email:</b> support@mdsas.com</div><div><a href="http://www.nhr.nhs.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nhr.nhs.uk</a></div></li></ul></div><div id="b-thal.Molecular_Genetics"><h2 id="_b-thal_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="b-thal.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Beta-Thalassemia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_b-thal.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_b-thal.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_b-thal.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_b-thal.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_b-thal.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_b-thal.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_b-thal.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3043" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HBB</i></a></td><td headers="hd_b_b-thal.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3043" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11p15<wbr style="display:inline-block"></wbr>​.4</a></td><td headers="hd_b_b-thal.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P68871" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemoglobin subunit beta</a></td><td headers="hd_b_b-thal.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/HBB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBB @ LOVD</a><br /><a href="http://globin.cse.psu.edu/globin/hbvar/menu.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HbVar: A Database of Human Hemoglobin Variants and Thalassemias (HBB)</a></td><td headers="hd_b_b-thal.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HBB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBB</a></td><td headers="hd_b_b-thal.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HBB[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBB</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="b-thal.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="b-thal.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Beta-Thalassemia (<a href="/omim/141900,613985" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/141900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">141900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOGLOBIN--BETA LOCUS; HBB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613985" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613985</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BETA-THALASSEMIA</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>HBB</i>, which spans 1.6 kb, contains three exons and both 5' and 3' untranslated regions. <i>HBB</i> is regulated by an adjacent 5' promoter, which contains a TATA, CAAT, and duplicated CACCC boxes, and an upstream regulatory element dubbed the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> control region (LCR). A number of transcription factors regulate the function of <i>HBB</i>, the most important of which is the erythroid Kruppel-like factor (EKLF), which binds the proximal CACCC box. <i>HBB</i> is contained within the <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster, which includes <i>HBD</i>, <i>HBG1</i>, <i>HBG2</i>, and an <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a>, <i>HBBP1</i>. For a detailed summary of gene and protein information, see <a href="/books/NBK1426/#b-thal.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Almost 300 beta-thalassemia alleles have now been characterized (<a href="http://globin.cse.psu.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">globin.cse.psu.edu</a>). The large majority are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, or frameshift variants. Rarely, the &#x003b2;-thalassemias are the result of gross <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>. Classes of pathogenic variants:</p><ul><li class="half_rhythm"><div>&#x003b2;&#x000ba;-thalassemia (complete absence of hemoglobin subunit beta production) alleles resulting from <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, or (sometimes) <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants</div></li><li class="half_rhythm"><div>&#x003b2;<sup>+</sup>-thalassemia alleles (residual output of globin beta chains) resulting from pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions, the promoter area (either the CACCC or the TATA box), the polyadenylation signal, or the 5' or 3' untranslated region, or by <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> abnormalities</div></li><li class="half_rhythm"><div>Complex &#x003b2;-thalassemias (delta-beta- and gamma-delta-beta-thalassemia) resulting from <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of variable extent of the <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster [<a class="bk_pop" href="#b-thal.REF.rooks.2005.722">Rooks et al 2005</a>]</div></li><li class="half_rhythm"><div>&#x003b2;-thalassemia caused by <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of the LCR (leaving <i>HBB</i> intact) [<a class="bk_pop" href="#b-thal.REF.joly.2011.316">Joly et al 2011</a>]</div></li><li class="half_rhythm"><div>Rarely, pathogenic variants outside the &#x003b2;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster (TFIIH and GATA-1)</div></li></ul><p>Population-specific pathogenic variants are common (see <a class="figpopup" href="/books/NBK1426/table/b-thal.T.selected_hbb_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figbthalTselectedhbbpathogenicvariant" rid-ob="figobbthalTselectedhbbpathogenicvariant">Table 4</a>), with four to ten variants usually accounting for most of the <i>HBB</i> pathogenic variants.</p><p>Note: Phenotypes of gamma-delta-beta-thalassemia and of &#x003b2;-thalassemia caused by <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of the LCR in adult carriers (microcytic, hypocromic anemia with normal levels of HbA2) may be mistaken for alpha-thalassemia trait.</p><div id="b-thal.T.selected_hbb_pathogenic_variant" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>HBB</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.T.selected_hbb_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.T.selected_hbb_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change&#x000a0;<sup>1</sup><br />(Alias&#x000a0;<sup>2</sup>)</th><th id="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change&#x000a0;<sup>1</sup><br />(Alias&#x000a0;<sup>2</sup>)</th><th id="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At-Risk Populations</th><th id="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Detection Frequency</th><th id="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-136C&#x0003e;G<br />(-87C&#x0003e;G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">Mediterranean</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_4" rowspan="22" colspan="1" style="text-align:left;vertical-align:middle;">91%-95%</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_5" rowspan="28" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000518.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000518<wbr style="display:inline-block"></wbr>​.4 </a></td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.92+1G&#x0003e;A<br />(IVS1-1G&#x0003e;A)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.92+6T&#x0003e;C<br />(IVS1-6T&#x0003e;C)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.93-21G&#x0003e;A<br />(IVS1-110G&#x0003e;A)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.118C&#x0003e;T<br />(cd39C&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln40Ter<br />(p.Gln39Ter)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.316-106C&#x0003e;G<br />(IVS2-745C&#x0003e;G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.25_26delAA<br />(cd8-AA)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lys9ValfsTer14<br />(p.Lys8ValfsTer13)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">Middle East</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.27dupG<br />(cd8/9+G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ser10ValfsTer14<br />(p.Ser9ValfsTer13)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.92+5G&#x0003e;C<br />(IVS1-5G&#x0003e;C)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.118C&#x0003e;T<br />(cd39C&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln40Ter<br />(p.Gln39Ter)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.135delC<br />(cd44-C)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phe46LeufsTer16<br />(p.Phe45LeufsTer15)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.315+1G&#x0003e;A<br />(IVS2-1G&#x0003e;A)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-78A&#x0003e;G<br />(-28A&#x0003e;G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">Thai</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.52A&#x0003e;T<br />(17A&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys18Ter<br />(p.Lys17Ter)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.59A&#x0003e;G<br />(19A&#x0003e;G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn20Ser<br />(p.Asn19Ser)<br />(Hb Malay)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.92+5G&#x0003e;C<br />(IVS1-5G&#x0003e;C)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.126_129delCTTT<br />(c.124_127delTTCT)<br />(41/42-TTCT)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phe42LeufsTer19<br />(p.Phe42LeufsTer17)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.316-197C&#x0003e;T<br />(IVS2-654C&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-78A&#x0003e;G<br />(-28A&#x0003e;G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Chinese</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.52A&#x0003e;T<br />(17A&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys18Ter<br />(p.Lys17Ter)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.126_129delCTTT<br />(c.124_127delTTCT)<br />(41/42-TTCT)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phe42LeufsTer19<br />(p.Phe42LeufsTer17)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.316-197C&#x0003e;T<br />(IVS2-654C&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-138C&#x0003e;T<br />(-88C&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">African / African American</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_4" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">75%-80%</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-79A&#x0003e;G<br />(-29A&#x0003e;G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.92+5G&#x0003e;C<br />(IVS1-5G&#x0003e;T)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.75T&#x0003e;A<br />(cd24T&#x0003e;A)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly25=<br />(p.Gly24=)</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.316-2A&#x0003e;G<br />(IVS11-849A&#x0003e;G)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.316-2A&#x0003e;C<br />(IVS11-849A&#x0003e;C)</td><td headers="hd_h_b-thal.T.selected_hbb_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="b-thal.TF.4.1"><p class="no_margin">Variant nomenclature following current guidelines has been provided. However, because the initiation methionine is not part of the mature beta-globin protein, the longstanding convention of numbering the amino acids is to begin with the next amino acid (Val). For consistency with the literature and the Globin Gene Server (<a href="http://globin.cse.psu.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">globin<wbr style="display:inline-block"></wbr>​.cse.psu.edu</a>), the traditional amino acid numbering has been provided.</p></div></dd><dt>2. </dt><dd><div id="b-thal.TF.4.2"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p>Silent variants, which are characterized by normal hematologic findings and defined only by a mildly unbalanced &#x003b1;/&#x003b2;-globin chain synthesis ratio, result from pathogenic variants in the distal CACCC box, the 5' unbalanced region, the polyadenylation signal, and some <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects (see <a class="figpopup" href="/books/NBK1426/table/b-thal.T.mild_and_silent_hbb_pathogenic/?report=objectonly" target="object" rid-figpopup="figbthalTmildandsilenthbbpathogenic" rid-ob="figobbthalTmildandsilenthbbpathogenic">Table 5</a>).</p><div id="b-thal.T.mild_and_silent_hbb_pathogenic" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Mild and Silent <i>HBB</i> Pathogenic Variants Causing &#x003b2;-Thalassemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1426/table/b-thal.T.mild_and_silent_hbb_pathogenic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__b-thal.T.mild_and_silent_hbb_pathogenic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" style="text-align:left;vertical-align:middle;">Variant Type or Location</th><th id="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard Naming Conventions&#x000a0;<sup>1</sup></th><th id="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Aliases&#x000a0;<sup>2</sup></th></tr><tr><th headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2" id="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Predicted Protein Change)</th><th headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3" id="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild &#x003b2;<sup>+</sup></th><th headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3" id="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Silent</th></tr></thead><tbody><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Transcriptional variants in the proximal CACC box</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-140C&#x0003e;T<br />c.-138C&#x0003e;T<br />c.-138C&#x0003e;A<br />c.-137C&#x0003e;T<br />c.-137C&#x0003e;G<br />c.-137C&#x0003e;A<br />c.-136C&#x0003e;T<br />c.-136C&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-90 C&#x0003e;T<br />-88 C&#x0003e;T<br />-88 C&#x0003e;A<br />-87 C&#x0003e;T<br />-87 C&#x0003e;G<br />-87 C&#x0003e;A<br />-86 C&#x0003e;T<br />-86 C&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.-151C&#x0003e;T<br />c.-142C&#x0003e;T</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-101 C&#x0003e;T<br />-92 C&#x0003e;T</td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TATA box</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-81A&#x0003e;G<br />c.-80T&#x0003e;A<br />c.-79A&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-31 A&#x0003e;G<br />-30 T&#x0003e;A<br />-29 A&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">5' UTR</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-29G&#x0003e;A<br />c.-41de&#x0003e;T<br />c.-18C&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+22 G&#x0003e;A<br />+10 -T<br />+33 C&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.-50A&#x0003e;C</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+1' A&#x0003e;C</td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.59A&#x0003e;G (p.Asn20Ser<br />(c.56A&#x0003e;G; p.Asn19Ser)&#x000a0;<sup>3</sup></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">cd19 A&#x0003e;C<br />Hb Malay</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">c.72T&#x0003e;A (p.Gly25=)<br />(p.Gly24=)&#x000a0;<sup>3</sup></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">cd24 T&#x0003e;A</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.82G&#x0003e;T (p.Ala28Ser)<br />(p.Ala27Ser)&#x000a0;<sup>3</sup></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">cd27 G&#x0003e;T (Hb Knossos)</td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consensus <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.92+6T&#x0003e;C</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">IVS1-6 T&#x0003e;C</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intron</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.316-7C&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">IVS2-844 C&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3' UTR</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.*6C&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+6 C&#x0003e;G</td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Poly A site</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.*110T&#x0003e;C<br />c.*111A&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AACAAA<br />AATGAA</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.*113A&#x0003e;G</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AATAAG</td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Mild &#x003b2;&#x000ba; (frameshift)</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.20delA (p.Glu7GlyfsTer13)<br />(c.17delA; p.Glu6GlyfsTer12)&#x000a0;<sup>3</sup></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">cd6-A</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_2 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.25_26delAA (p.Lys9ValfsTer14)<br />(p.Lys8ValfsTer13)&#x000a0;<sup>3</sup></td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cd8-AA</td><td headers="hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_1_3 hd_h_b-thal.T.mild_and_silent_hbb_pathogenic_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="b-thal.TF.5.1"><p class="no_margin">Reference sequence is NM_000518 (<a href="/Genbank/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www<wbr style="display:inline-block"></wbr>​.ncbi.nlm.nih.gov/Genbank</a>).</p></div></dd><dt>2. </dt><dd><div id="b-thal.TF.5.2"><p class="no_margin">Nonstandard variant designations in common use (<a href="http://globin.cse.psu.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">globin<wbr style="display:inline-block"></wbr>​.cse.psu.edu</a>)</p></div></dd><dt>3. </dt><dd><div id="b-thal.TF.5.3"><p class="no_margin">Variant nomenclature following current guidelines has been provided. However, because the initiation methionine is not part of the mature beta-globin protein, the long-standing convention of numbering the amino acids is to begin with the next amino acid (Val). For consistency with the literature and the Globin Gene Server (<a href="http://globin.cse.psu.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">globin<wbr style="display:inline-block"></wbr>​.cse.psu.edu</a>), the traditional amino acid numbering has been provided in this table.</p></div></dd></dl></div></div></div><p>For more information, see <a href="/books/NBK1426/#b-thal.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>HBB</i> encodes hemoglobin subunit beta. The heterodimeric protein HbA is made up of two globin alpha chains and two globin beta chains.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> &#x003b2;&#x000ba;-thalassemia results from the absence of globin beta chains. In &#x003b2;<sup>+</sup>-thalassemia, the globin beta chain output is reduced to a variable extent, but the globin beta chains have a normal sequence.</p></div><div id="b-thal.References"><h2 id="_b-thal_References_">References</h2><div id="b-thal.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.allen.2017.73">Allen S, Young E, Bowns B. Noninvasive prenatal diagnosis for single gene disorders. <span><span class="ref-journal">Curr Opin Obstet Gynecol. </span>2017;<span class="ref-vol">29</span>:73–9.</span> [<a href="/pubmed/28134670" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28134670</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.anderson.2002.516">Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. <span><span class="ref-journal">Lancet. </span>2002;<span class="ref-vol">360</span>:516–20.</span> [<a href="/pubmed/12241655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12241655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.angastiniotis.2013">Angastiniotis M, Eleftheriou A, Galanello R, Harteveld CL, Petrou M, Traeger-Synodinos J, Giordano P, Jauniaux E, Modell B, Serour G. <em>Prevention of Thalassaemias and Other Haemoglobin Disorders. Vol 1: Principles.</em> 2 ed. Nicosia, Cyprus: Thalassaemia International Federation. Available <a href="http://ukts.org/pdfs/tifpubs/preventionv1.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 1-10-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.anurathapan.2016.813">Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Rujkijyanont P, Meekaewkunchorn A, Lektrakul Y, Iamsirirak P, Surapolchai P, Satayasai W, Sirireung S, Sruamsiri R, Wahidiyat PA, Ungkanont A, Issaragrisil S, Andersson BS. Hematopoietic stem cell transplantation for homozygous &#x003b2;-thalassemia and &#x003b2;-thalassemia/hemoglobin E patients from haploidentical donors. <span><span class="ref-journal">Bone Marrow Transplant. </span>2016;<span class="ref-vol">51</span>:813–8.</span> [<a href="/pmc/articles/PMC4957689/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4957689</span></a>] [<a href="/pubmed/26878659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26878659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.aydinok.2015a.3868">Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, Kilin&#x000e7; Y, Perrotta S, Karakas Z, Viprakasit V, Habr D, Constantinovici N, Shen J, Porter JB. HYPERION Investigators. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. <span><span class="ref-journal">Blood. </span>2015a;<span class="ref-vol">125</span>:3868–77.</span> [<a href="/pmc/articles/PMC4490296/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4490296</span></a>] [<a href="/pubmed/25934475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25934475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.aydinok.2015b.244">Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilin&#x000e7; Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. <span><span class="ref-journal">Eur J Haematol. </span>2015b;<span class="ref-vol">95</span>:244–53.</span> [<a href="/pubmed/25418187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25418187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.baronciani.2016.536">Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipek A, Zecca M, Orofino MG, Giardini C, Al-Ahmari A, Marktel S, de la Fuente J, Ghavamzadeh A, Hussein AA, Targhetta C, Pilo F, Locatelli F, Dini G, Bader P, Peters C. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. <span><span class="ref-journal">Bone Marrow Transplant. </span>2016;<span class="ref-vol">51</span>:536–41.</span> [<a href="/pubmed/26752139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26752139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.berdoukas.2010.1177">Berdoukas V, Carson S, Nord A, Dongelyan A, Gavin S, Hofstra TC, Wood JC, Coates T. Combining two orally active iron chelators for thalassemia. <span><span class="ref-journal">Ann Hematol. </span>2010;<span class="ref-vol">89</span>:1177–8.</span> [<a href="/pubmed/20217085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20217085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.borg.2010.801">Borg J, Papadopoulos P, Georgitsi M, Guti&#x000e9;rrez L, Grech G, Fanis P, Phylactides M, Verkerk AJ, van der Spek PJ, Scerri CA, Cassar W, Galdies R, van Ijcken W, Ozg&#x000fc;r Z, Gillemans N, Hou J, Bugeja M, Grosveld FG, von Lindern M, Felice AE, Patrinos GP, Philipsen S. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:801–5.</span> [<a href="/pmc/articles/PMC2930131/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2930131</span></a>] [<a href="/pubmed/20676099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20676099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.borgnapignatti.2014.121">Borgna-Pignatti C, Garani MC, Forni GL, Cappellini MD, Cassinerio E, Fidone C, Spadola V, Maggio A, Restivo Pantalone G, Piga A, Longo F, Gamberini MR, Ricchi P, Costantini S, D'Ascola D, Cianciulli P, Lai ME, Carta MP, Ciancio A, Cavalli P, Putti MC, Barella S, Amendola G, Campisi S, Capra M, Caruso V, Colletta G, Volpato S. Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. <span><span class="ref-journal">Br J Haematol. </span>2014;<span class="ref-vol">167</span>:121–6.</span> [<a href="/pubmed/24992281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24992281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.borgnapignatti.2004.114">Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG. Hepatocellular carcinoma in the thalassaemia syndromes. <span><span class="ref-journal">Br J Haematol. </span>2004;<span class="ref-vol">124</span>:114–7.</span> [<a href="/pubmed/14675416" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14675416</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.bradai.2003.1529">Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">102</span>:1529–30.</span> [<a href="/pubmed/12702505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12702505</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.breda.2014.375">Breda L, Rivella S. Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2014;<span class="ref-vol">28</span>:375–86.</span> [<a href="/pmc/articles/PMC3970239/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3970239</span></a>] [<a href="/pubmed/24589272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24589272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.cappellini.2008.s35">Cappellini MD. Long-term efficacy and safety of deferasirox. <span><span class="ref-journal">Blood Rev. </span>2008;<span class="ref-vol">22</span> Suppl 2:S35–41.</span> [<a href="/pubmed/19059055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19059055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.cappellini.2014">Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. <em>Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)</em>. 3 ed. Thalassemia International Foundation; 2014.</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.cappellini.2012.s20">Cappellini MD, Musallam KM, Poggiali E, Taher AT. Hypercoagulability in non-transfusion-dependent thalassemia. <span><span class="ref-journal">Blood Rev. </span>2012;<span class="ref-vol">26</span> Suppl 1:S20–3.</span> [<a href="/pubmed/22631037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22631037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.carpenter.2011.1519">Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ. On T2* magnetic resonance and cardiac iron. <span><span class="ref-journal">Circulation. </span>2011;<span class="ref-vol">123</span>:1519–28.</span> [<a href="/pmc/articles/PMC3435874/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3435874</span></a>] [<a href="/pubmed/21444881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21444881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.casu.2016.265">Casu C, Oikonomidou PR, Chen H, Nandi V, Ginzburg Y, Prasad P, Fleming RE, Shah YM, Valore EV, Nemeth E, Ganz T, MacDonald B, Rivella S. Minihepcidin peptides as disease modifiers in mice affected by &#x003b2;-thalassemia and polycythemia vera. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">128</span>:265–76.</span> [<a href="/pmc/articles/PMC4946204/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4946204</span></a>] [<a href="/pubmed/27154187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27154187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.cavazzanacalvo.2010.318">Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chr&#x000e9;tien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chr&#x000e9;tien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P. Transfusion independence and HMGA2 activation after gene therapy of human &#x003b2;-thalassaemia. <span><span class="ref-journal">Nature. </span>2010;<span class="ref-vol">467</span>:318–22.</span> [<a href="/pmc/articles/PMC3355472/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3355472</span></a>] [<a href="/pubmed/20844535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20844535</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.chavassieux.2014.618">Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate. <span><span class="ref-journal">J Bone Miner Res. </span>2014;<span class="ref-vol">29</span>:618–28.</span> [<a href="/pubmed/23959630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23959630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.chouliaras.2011.56">Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. <span><span class="ref-journal">J Magn Reson Imaging. </span>2011;<span class="ref-vol">34</span>:56–9.</span> [<a href="/pubmed/21608067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21608067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.clark.2003.572">Clark PR, Chua-Anusorn W, St Pierre TG. Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI. <span><span class="ref-journal">Magn Reson Med. </span>2003;<span class="ref-vol">49</span>:572–5.</span> [corrected] [<a href="/pubmed/12594762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12594762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.cottle.2016.993">Cottle RN, Lee CM, Bao G. Treating hemoglobinopathies using gene correction approaches: promises and challenges. <span><span class="ref-journal">Hum Genet. </span>2016;<span class="ref-vol">135</span>:993–1010.</span> [<a href="/pmc/articles/PMC5002253/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5002253</span></a>] [<a href="/pubmed/27314256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27314256</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.creary.2009.e4218">Creary LE, Ulug P, Menzel S, McKenzie CA, Hanchard NA, Taylor V, Farrall M, Forrester TE, Thein SL. Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. <span><span class="ref-journal">PLoS One. </span>2009;<span class="ref-vol">4</span>:e4218.</span> [<a href="/pmc/articles/PMC2621086/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2621086</span></a>] [<a href="/pubmed/19148297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19148297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.danjou.2015.452">Danjou F, Francavilla M, Anni F, Satta S, Demartis FR, Perseu L, Manca M, Sollaino MC, Manunza L, Mereu E, Marceddu G, Pissard S, Joly P, Thuret I, Origa R, Borg J, Forni GL, Piga A, Lai ME, Badens C, Moi P, Galanello R. A genetic score for the prediction of beta-thalassemia severity. <span><span class="ref-journal">Haematologica. </span>2015;<span class="ref-vol">100</span>:452–7.</span> [<a href="/pmc/articles/PMC4380717/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4380717</span></a>] [<a href="/pubmed/25480500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25480500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.dede.2016.3409">Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I, Papaioannou N, Tournis S. Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. <span><span class="ref-journal">Osteoporos Int. </span>2016;<span class="ref-vol">27</span>:3409–25.</span> [<a href="/pubmed/27503175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27503175</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.dussiot.2014.398">Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, Grapton D, Paubelle E, Payen E, Beuzard Y, Leboulch P, Ribeil JA, Arlet JB, Cot&#x000e9; F, Courtois G, Ginzburg YZ, Daniel TO, Chopra R, Sung V, Hermine O, Moura IC. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in &#x003b2;-thalassemia. <span><span class="ref-journal">Nat Med. </span>2014;<span class="ref-vol">20</span>:398–407.</span> [<a href="/pubmed/24658077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24658077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.elalfy.2015.411">Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. <span><span class="ref-journal">Eur J Haematol. </span>2015;<span class="ref-vol">95</span>:411–20.</span> [<a href="/pubmed/25600572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25600572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.farmaki.2011.33">Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2011;<span class="ref-vol">47</span>:33–40.</span> [<a href="/pubmed/21531154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21531154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.ferrari.2017.835">Ferrari G, Cavazzana M, Mavilio F. Gene therapy approaches to hemoglobinopathies. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2017;<span class="ref-vol">31</span>:835–52.</span> [<a href="/pubmed/28895851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28895851</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.fischer.2003.938">Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. <span><span class="ref-journal">Br J Haematol. </span>2003;<span class="ref-vol">121</span>:938–48.</span> [<a href="/pubmed/12786807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12786807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.freson.2002.147">Freson K, Matthijs G, Thys C, Mari&#x000eb;n P, Hoylaerts MF, Vermylen J, Van Geet C. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:147–52.</span> [<a href="/pubmed/11809723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11809723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.galanello.2010.79">Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. <span><span class="ref-journal">Ann N Y Acad Sci. </span>2010;<span class="ref-vol">1202</span>:79–86.</span> [<a href="/pubmed/20712777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20712777</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.galanello.2009.155">Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. <span><span class="ref-journal">Acta Haematol. </span>2009;<span class="ref-vol">122</span>:155–64.</span> [<a href="/pubmed/19907153" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19907153</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.galanello.1979.33">Galanello R, Melis MA, Ruggeri R, Addis M, Scalas MT, Maccioni L, Furbetta M, Angius A, Tuveri T, Cao A. Beta 0 thalassemia trait in Sardinia. <span><span class="ref-journal">Hemoglobin. </span>1979;<span class="ref-vol">3</span>:33–46.</span> [<a href="/pubmed/457422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 457422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.galanello.2009.3935">Galanello R, Sanna S, Perseu L, Sollaino MC, Satta S, Lai ME, Barella S, Uda M, Usala G, Abecasis GR, Cao A. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">114</span>:3935–7.</span> [<a href="/pmc/articles/PMC2925722/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2925722</span></a>] [<a href="/pubmed/19696200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19696200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.gallienne.2012.340">Gallienne AE, Dr&#x000e9;au HM, Schuh A, Old JM, Henderson S. Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults. <span><span class="ref-journal">Haematologica. </span>2012;<span class="ref-vol">97</span>:340–3.</span> [<a href="/pmc/articles/PMC3291586/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3291586</span></a>] [<a href="/pubmed/22102705" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22102705</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.gaziev.2013.2751">Gaziev J, Marziali M, Isgr&#x000f2; A, Sodani P, Paciaroni K, Gallucci C, Andreani M, Testi M, De Angelis G, Alfieri C, Cardarelli L, Ribersani M, Armiento D, Lucarelli G. Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">122</span>:2751–6.</span> [<a href="/pubmed/23963044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23963044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.giusti.2014.606">Giusti A. Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. <span><span class="ref-journal">J Bone Miner Metab. </span>2014;<span class="ref-vol">32</span>:606–15.</span> [<a href="/pubmed/24748165" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24748165</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.hahn.2011.e16">Hahn S, Lapaire O, Tercanli S, Kolla V, H&#x000f6;sli I. Determination of fetal chromosome aberrations from fetal DNA in maternal blood: has the challenge finally been met? <span><span class="ref-journal">Expert Rev Mol Med. </span>2011;<span class="ref-vol">13</span>:e16.</span> [<a href="/pmc/articles/PMC3087311/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3087311</span></a>] [<a href="/pubmed/21542948" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21542948</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.harteveld.2008.312">Harteveld CL, Refaldi C, Cassinerio E, Cappellini MD, Giordano PC. Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassemia intermedia phenotypes in beta-thalassemia heterozygous patients. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2008;<span class="ref-vol">40</span>:312–6.</span> [<a href="/pubmed/18249014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18249014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.harteveld.2012">Harteveld CL, Traeger-Synodinos J, Petrou M, Angastiniotis M, Galanello R. <em>Prevention of Thalassaemias and Other Haemoglobin Disorders. Vol 2: Laboratory Protocols</em>. 2 ed. Nicosia, Cyprus: Thalassaemia International Federation. Available <a href="http://ukts.org/pdfs/tifpubs/preventionv2.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 1-10-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.harteveld.2005.922">Harteveld CL, Voskamp A, Phylipsen M, Akkermans N, den Dunnen JT, White SJ, Giordano PC. Nine unknown rearrangements in 16p13.3 and 11p15.4 causing alpha- and beta-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:922–31.</span> [<a href="/pmc/articles/PMC1735959/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735959</span></a>] [<a href="/pubmed/15894596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15894596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.jaing.2012.33">Jaing TH, Hung IJ, Yang CP, Chen SH, Chung HT, Tsay PK, Wen YC. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. <span><span class="ref-journal">Bone Marrow Transplant. </span>2012;<span class="ref-vol">47</span>:33–9.</span> [<a href="/pubmed/21383683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21383683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.joly.2011.316">Joly P, Lacan P, Garcia C, Meley R, Pondarr&#x000e9; C, Francina A. A novel deletion/insertion caused by a replication error in the &#x003b2;-globin gene locus control region. <span><span class="ref-journal">Hemoglobin. </span>2011;<span class="ref-vol">35</span>:316–22.</span> [<a href="/pubmed/21797698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21797698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.karimi.2009.213">Karimi M, Borzouee M, Mehrabani A, Cohan N. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. <span><span class="ref-journal">Eur J Haematol. </span>2009;<span class="ref-vol">82</span>:213–8.</span> [<a href="/pubmed/19077048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19077048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.kirk.2009.1961">Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. <span><span class="ref-journal">Circulation. </span>2009;<span class="ref-vol">120</span>:1961–8.</span> [<a href="/pmc/articles/PMC2784198/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2784198</span></a>] [<a href="/pubmed/19801505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19801505</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.kolialexi.2007.1228">Kolialexi A, Vrettou C, Traeger-Synodinos J, Burgemeister R, Papantoniou N, Kanavakis E, Antsaklis A, Mavrou A. Noninvasive prenatal diagnosis of beta-thalassaemia using individual fetal erythroblasts isolated from maternal blood after enrichment. <span><span class="ref-journal">Prenat Diagn. </span>2007;<span class="ref-vol">27</span>:1228–32.</span> [<a href="/pubmed/17987605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17987605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.la_nasa.2005.186">La Nasa G, Argiolu F, Giardini C, Pession A, Fagioli F, Caocci G, Vacca A, De Stefano P, Piras E, Ledda A, Piroddi A, Littera R, Nesci S, Locatelli F. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. <span><span class="ref-journal">Ann N Y Acad Sci. </span>2005;<span class="ref-vol">1054</span>:186–95.</span> [<a href="/pubmed/16339665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16339665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.lam.2012.1467">Lam KW, Jiang P, Liao GJ, Chan KC, Leung TY, Chiu RW, Lo YM. Noninvasive prenatal diagnosis of monogenic diseases by targeted massively parallel sequencing of maternal plasma: application to &#x003b2;-thalassemia. <span><span class="ref-journal">Clin Chem. </span>2012;<span class="ref-vol">58</span>:1467–75.</span> [<a href="/pubmed/22896714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22896714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.lettre.2008.11869">Lettre G, Sankaran VG, Bezerra MA, Ara&#x000fa;jo AS, Uda M, Sanna S, Cao A, Schlessinger D, Costa FF, Hirschhorn JN, Orkin SH. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2008;<span class="ref-vol">105</span>:11869–74.</span> [<a href="/pmc/articles/PMC2491485/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2491485</span></a>] [<a href="/pubmed/18667698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18667698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.levin.2011.316">Levin C, Koren A. Healing of refractory leg ulcer in a patient with thalassemia intermedia and hypercoagulability after 14 years of unresponsive therapy. <span><span class="ref-journal">Isr Med Assoc J. </span>2011;<span class="ref-vol">13</span>:316–8.</span> [<a href="/pubmed/21845977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21845977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.lun.2008.19920">Lun FM, Tsui NB, Chan KC, Leung TY, Lau TK, Charoenkwan P, Chow KC, Lo WY, Wanapirak C, Sanguansermsri T, Cantor CR, Chiu RW, Lo YM. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2008;<span class="ref-vol">105</span>:19920–5.</span> [<a href="/pmc/articles/PMC2596743/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2596743</span></a>] [<a href="/pubmed/19060211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19060211</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.modell.2008.42">Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. <span><span class="ref-journal">J Cardiovasc Magn Reson. </span>2008;<span class="ref-vol">10</span>:42.</span> [<a href="/pmc/articles/PMC2563008/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563008</span></a>] [<a href="/pubmed/18817553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18817553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.moukhadder.2017.751">Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. <span><span class="ref-journal">Cancer. </span>2017;<span class="ref-vol">123</span>:751–8.</span> [<a href="/pubmed/27911488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27911488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.negre.2016.148">Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S, Hongeng S, Hacein-Bey S, Cavazzana M, Leboulch P, Payen E. Gene therapy of the &#x003b2;-hemoglobinopathies by lentiviral transfer of the &#x003b2;(A(T87Q))-globin gene. <span><span class="ref-journal">Hum Gene Ther. </span>2016;<span class="ref-vol">27</span>:148–65.</span> [<a href="/pmc/articles/PMC4779296/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4779296</span></a>] [<a href="/pubmed/26886832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26886832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.nemeth.2006.727">Nemeth E, Ganz T. Hepcidin and iron-loading anemias. <span><span class="ref-journal">Haematologica. </span>2006;<span class="ref-vol">91</span>:727–32.</span> [<a href="/pubmed/16769573" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769573</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.origa.2007.583">Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in beta-thalassemia. <span><span class="ref-journal">Haematologica. </span>2007;<span class="ref-vol">92</span>:583–8.</span> [<a href="/pubmed/17488680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17488680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.origa.2009.22">Origa R, Galanello R, Perseu L, Tavazzi D. DomenicaCappellini M, Terenzani L, Forni GL, Quarta G, Boetti T, Piga A. Cholelithiasis in thalassemia major. <span><span class="ref-journal">Eur J Haematol. </span>2009;<span class="ref-vol">82</span>:22–5.</span> [<a href="/pubmed/19021734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19021734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.origa.2010.376">Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, Galanello R. Pregnancy and beta-thalassemia: an Italian multicenter experience. <span><span class="ref-journal">Haematologica. </span>2010;<span class="ref-vol">95</span>:376–81.</span> [<a href="/pmc/articles/PMC2833066/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2833066</span></a>] [<a href="/pubmed/19903676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19903676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.origa.2008.143">Origa R, Satta S, Matta G, Galanello R. Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major. <span><span class="ref-journal">Br J Haematol. </span>2008;<span class="ref-vol">142</span>:143–5.</span> [<a href="/pubmed/18477036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18477036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.origa.2014.162">Origa R, Sollaino MC, Borgna-Pignatti C, Piga A, Feliu Torres A, Masile V, Galanello R. &#x003b1;-globin gene quadruplication and heterozygous &#x003b2;-thalassemia: a not so rare cause of thalassemia intermedia. <span><span class="ref-journal">Acta Haematol. </span>2014;<span class="ref-vol">131</span>:162–4.</span> [<a href="/pubmed/24217654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24217654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.orofino.2003.41">Orofino MG, Argiolu F, Sanna MA, Rosatelli MC, Tuveri T, Scalas MT, Badiali M, Cossu P, Puddu R, Lai ME, Cao A. Fetal HLA typing in beta thalassaemia: implications for haemopoietic stem-cell transplantation. <span><span class="ref-journal">Lancet. </span>2003;<span class="ref-vol">362</span>:41–2.</span> [<a href="/pubmed/12853199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12853199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.pennell.2005.373">Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. <span><span class="ref-journal">Ann N Y Acad Sci. </span>2005;<span class="ref-vol">1054</span>:373–8.</span> [<a href="/pubmed/16339685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16339685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.pennell.2006.3738">Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">107</span>:3738–44.</span> [<a href="/pubmed/16352815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16352815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.pennell.2012.842">Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with &#x003b2;-thalassemia major. <span><span class="ref-journal">Haematologica. </span>2012;<span class="ref-vol">97</span>:842–8.</span> [<a href="/pmc/articles/PMC3366648/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3366648</span></a>] [<a href="/pubmed/22271905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22271905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.pennell.2014.1447">Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilin&#x000e7; Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y., CORDELIA study investigators.  A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in &#x003b2;-thalassemia major (CORDELIA). <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:1447–54.</span> [<a href="/pmc/articles/PMC3945858/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3945858</span></a>] [<a href="/pubmed/24385534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24385534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.persons.2009.690">Persons DA. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2009:690–7.</span> [<a href="/pubmed/20008255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20008255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.phylipsen.2012.578">Phylipsen M, Yamsri S, Treffers EE, Jansen DT, Kanhai WA, Boon EM, Giordano PC, Fucharoen S, Bakker E, Harteveld CL. Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis. <span><span class="ref-journal">Prenat Diagn. </span>2012;<span class="ref-vol">32</span>:578–87.</span> [<a href="/pubmed/22517437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22517437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.piga.2003.489">Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. <span><span class="ref-journal">Haematologica. </span>2003;<span class="ref-vol">88</span>:489–96.</span> [<a href="/pubmed/12745268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12745268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.pinto.2008.309">Pinto FO, Roberts I. Cord blood stem cell transplantation for haemoglobinopathies. <span><span class="ref-journal">Br J Haematol. </span>2008;<span class="ref-vol">141</span>:309–24.</span> [<a href="/pubmed/18307566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18307566</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.ramos.2012.3829">Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">120</span>:3829–36.</span> [<a href="/pmc/articles/PMC3488893/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3488893</span></a>] [<a href="/pubmed/22990014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22990014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.reading.2016.1153">Reading NS, Shooter C, Song J, Miller R, Agarwal A, Lanikova L, Clark B, Thein SL, Divoky V, Prchal JT. Loss of major DNase I hypersensitive sites in duplicated &#x003b2;-globin gene cluster incompletely silences HBB gene expression. <span><span class="ref-journal">Hum Mutat. </span>2016;<span class="ref-vol">37</span>:1153–6.</span> [<a href="/pubmed/27492747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27492747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.rooks.2005.722">Rooks H, Bergounioux J, Game L, Close JP, Osborne C, Best S, Senior T, Height S, Thompson R, Hadzic N, Fraser P, Bolton-Maggs P, Thein SL. Heterogeneity of the epsilon gamma delta beta-thalassaemias: characterization of three novel English deletions. <span><span class="ref-journal">Br J Haematol. </span>2005;<span class="ref-vol">128</span>:722–9.</span> [<a href="/pubmed/15725095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15725095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.ruggeri.2011.1375">Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, Wingard JR, Fasth A, Lo Nigro L, Ayas M, Purtill D, Boudjedir K, Chaves W, Walters MC, Wagner J, Gluckman E, Rocha V., Eurocord Registry, Center for International Blood and Marrow Transplant Research.  New York Blood Center. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. <span><span class="ref-journal">Biol Blood Marrow Transplant. </span>2011;<span class="ref-vol">17</span>:1375–82.</span> [<a href="/pmc/articles/PMC3395002/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3395002</span></a>] [<a href="/pubmed/21277376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21277376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.sankaran.2008.1839">Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. <span><span class="ref-journal">Science. </span>2008;<span class="ref-vol">322</span>:1839–42.</span> [<a href="/pubmed/19056937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19056937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.satta.2011.767">Satta S, Perseu L, Moi P, Asunis I, Cabriolu A, Maccioni L, Demartis FR, Manunza L, Cao A, Galanello R. Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. <span><span class="ref-journal">Haematologica. </span>2011;<span class="ref-vol">96</span>:767–70.</span> [<a href="/pmc/articles/PMC3084925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3084925</span></a>] [<a href="/pubmed/21273267" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21273267</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.shooter.2015.128">Shooter C, Senior McKenzie T, Oakley M, Jacques T, Clark B, Thein SL. First reported duplication of the entire beta globin gene cluster causing an unusual sickle cell trait phenotype. <span><span class="ref-journal">Br J Haematol. </span>2015;<span class="ref-vol">170</span>:128–31.</span> [<a href="/pubmed/25521162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25521162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.skordis.2011.300">Skordis N, Toumba M. Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects. <span><span class="ref-journal">Pediatr Endocrinol Rev. </span>2011;<span class="ref-vol">8</span>:300–6.</span> [<a href="/pubmed/21705982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21705982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.sodani.2011.e13">Sodani P, Isgr&#x000f2; A, Gaziev J, Paciaroni K, Marziali M, Simone MD, Roveda A, De Angelis G, Gallucci C, Torelli F, Isacchi G, Zinno F, Landi F, Adorno G, Lanti A, Testi M, Andreani M, Lucarelli G. T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients. <span><span class="ref-journal">Pediatr Rep. </span>2011;<span class="ref-vol">3</span>:e13.</span> [<a href="/pmc/articles/PMC3206538/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3206538</span></a>] [<a href="/pubmed/22053275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22053275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.sollaino.2009.1445">Sollaino MC, Paglietti ME, Perseu L, Giagu N, Loi D, Galanello R. Association of alpha globin gene quadruplication and heterozygous beta thalassemia in patients with thalassemia intermedia. <span><span class="ref-journal">Haematologica. </span>2009;<span class="ref-vol">94</span>:1445–8.</span> [<a href="/pmc/articles/PMC2754962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2754962</span></a>] [<a href="/pubmed/19794088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19794088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.suragani.2014.3864">Suragani RN, Cawley SM, Li R, Wallner S, Alexander MJ, Mulivor AW, Gardenghi S, Rivella S, Grinberg AV, Pearsall RS, Kumar R. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine &#x003b2;-thalassemia. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:3864–72.</span> [<a href="/pmc/articles/PMC4064330/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4064330</span></a>] [<a href="/pubmed/24795345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24795345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.taher.2013">Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. <em>Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT)</em>. Thalassemia International Foundation; 2013.</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.taher.2010.1886">Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:1886–92.</span> [<a href="/pubmed/20032507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20032507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.taher.2012.970">Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">120</span>:970–7.</span> [<a href="/pubmed/22589472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22589472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.tanner.2007.1876">Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. <span><span class="ref-journal">Circulation. </span>2007;<span class="ref-vol">115</span>:1876–84.</span> [<a href="/pubmed/17372174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17372174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.telen.1999">Telen MJ, Kaufman RE. The mature erythrocyte. In: Lee GR, Paraskevas F, Foerster J, Lukens J, eds. <em>Wintrobe&#x02019;s Clinical Hematology.</em> 10 ed. Baltimore, MD: Lippincott Williams &#x00026; Wilkins; 1999:207.</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.telfer.2006.1187">Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. <span><span class="ref-journal">Haematologica. </span>2006;<span class="ref-vol">91</span>:1187–92.</span> [<a href="/pubmed/16956817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16956817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.thein.2009.r216">Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:R216–23.</span> [<a href="/pmc/articles/PMC2758709/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2758709</span></a>] [<a href="/pubmed/19808799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19808799</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.traegersynodinos.2011.299">Traeger-Synodinos J, Vrettou C, Kanavakis E. Prenatal, noninvasive and preimplantation genetic diagnosis of inherited disorders: hemoglobinopathies. <span><span class="ref-journal">Expert Rev Mol Diagn. </span>2011;<span class="ref-vol">11</span>:299–312.</span> [<a href="/pubmed/21463239" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21463239</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.tungwiwat.2007.319">Tungwiwat W, Fucharoen G, Fucharoen S, Ratanasiri T, Sanchaisuriya K, Sae-Ung N. Application of maternal plasma DNA analysis for noninvasive prenatal diagnosis of Hb E-beta-thalassemia. <span><span class="ref-journal">Transl Res. </span>2007;<span class="ref-vol">150</span>:319–25.</span> [<a href="/pubmed/17964521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17964521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.uda.2008.1620">Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, Usala G, Busonero F, Maschio A, Albai G, Piras MG, Sestu N, Lai S, Dei M, Mulas A, Crisponi L, Naitza S, Asunis I, Deiana M, Nagaraja R, Perseu L, Satta S, Cipollina MD, Sollaino C, Moi P, Hirschhorn JN, Orkin SH, Abecasis GR, Schlessinger D, Cao A. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2008;<span class="ref-vol">105</span>:1620–5.</span> [<a href="/pmc/articles/PMC2234194/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2234194</span></a>] [<a href="/pubmed/18245381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18245381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.viprakasit.2001.2797">Viprakasit V, Gibbons RJ, Broughton BC, Tolmie JL, Brown D, Lunt P, Winter RM, Marinoni S, Stefanini M, Brueton L, Lehmann AR, Higgs DR. Mutations in the general transcription factor TFIIH result in beta-thalassaemia in individuals with trichothiodystrophy. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:2797–802.</span> [<a href="/pubmed/11734544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11734544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.voskaridou.2011.654">Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. <span><span class="ref-journal">Br J Haematol. </span>2011;<span class="ref-vol">154</span>:654–6.</span> [<a href="/pubmed/21615376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21615376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.voskaridou.2008.86">Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. <span><span class="ref-journal">Pediatr Endocrinol Rev. </span>2008;<span class="ref-vol">6</span> Suppl 1:86–93.</span> [<a href="/pubmed/19337161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19337161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.wood.2008.s14">Wood JC. Cardiac iron across different transfusion-dependent diseases. <span><span class="ref-journal">Blood Rev. </span>2008;<span class="ref-vol">22</span> Suppl 2:S14–21.</span> [<a href="/pmc/articles/PMC2896332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2896332</span></a>] [<a href="/pubmed/19059052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19059052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.xiong.2015.258">Xiong L, Barrett AN, Hua R, Tan TZ, Ho SS, Chan JK, Zhong M, Choolani M. Non-invasive prenatal diagnostic testing for &#x003b2;-thalassaemia using cell-free fetal DNA and next generation sequencing. <span><span class="ref-journal">Prenat Diagn. </span>2015;<span class="ref-vol">35</span>:258–65.</span> [<a href="/pubmed/25400264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25400264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.yassin.2014.546">Yassin MA, Soliman AT, De Sanctis V, Abdelrahman MO. AzizBedair EM, AbdelGawad M (2014) Effects of the anti-receptoractivator of nuclear factor kappa B ligand denusomab on betathalassemia major-induced osteoporosis. <span><span class="ref-journal">Indian J Endocrinol Metab. </span>2014;<span class="ref-vol">18</span>:546.</span> [<a href="/pmc/articles/PMC4138914/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4138914</span></a>] [<a href="/pubmed/25143915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25143915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.yavarian.2004.1172">Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. <span><span class="ref-journal">Haematologica. </span>2004;<span class="ref-vol">89</span>:1172–8.</span> [<a href="/pubmed/15477200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15477200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="b-thal.REF.zafari.2016.1341">Zafari M, Kosaryan M, Gill P, Alipour A, Shiran M, Jalalli H, Banihashemi A, Fatahi F. Non-invasive prenatal diagnosis of &#x003b2;-thalassemia by detection of the cell-free fetal DNA in maternal circulation: a systematic review and meta-analysis. <span><span class="ref-journal">Ann Hematol. </span>2016;<span class="ref-vol">95</span>:1341–50.</span> [<a href="/pubmed/26968552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26968552</span></a>]</div></li></ul></div></div><div id="b-thal.Chapter_Notes"><h2 id="_b-thal_Chapter_Notes_">Chapter Notes</h2><div id="b-thal.Author_Notes"><h3>Author Notes</h3><p><b>Antonio Cao, MD (1929-2012)</b></p><p>Antonio Cao, MD, Professor of Pediatrics at Cagliari University (Italy), was a world-renowned expert in the field of pediatrics and genetics. He was best known for his leadership role in understanding, diagnosing, preventing, and treating thalassemia. Among other honors, he received the Allan Award from the American Society of Human Genetics (1993) and the M&#x000e4;rta Philipson's Award for Progress in Paediatrics, given by the Karolinska Institutet, Stockholm (2000). Professor Cao was passionate about science and new discoveries, intuitive, demanding, and extremely innovative in his research; all of us in this field &#x02013; and our patients &#x02013; are deeply indebted to him for his work and his inspiration will continue to guide us in the years ahead. &#x02013; Renzo Galanello, MD</p><p><b>Renzo Galanello, MD (1948-2013)</b></p><p>Renzo Galanello, MD, Professor of Pediatrics at the University of Cagliari (Italy), was internationally recognized as an expert in the field of thalassemia, to which he contributed hundreds of papers. He was the right arm of his mentor Professor Antonio Cao in the program of thalassemia control in Sardinia. He defined the theoretical criteria, flow charts, and practical actuation of the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening for thalassemia as a prerequisite to <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>. The efficacy of the screening, tightly linked to the development of improved methods of prenatal diagnosis, led to the near-eradication of beta-thalassemia in Sardinia, establishing a model of disease control that was adopted in numerous other countries worldwide. Lately, he was among the leading scientists in the clinical validation of novel oral chelators and diagnostic assessment of cardiac iron overload. Dr Galanello was a member of national and international scientific societies and editorial committees of hematology journals, and scientific advisor of the Thalassemia International Federation, which expressed well the sad feelings of his friends and colleagues with the following commemorative words: "Professor Galanello, you will be greatly missed, but indeed all you have left behind as a doctor and a person will never be forgotten, will remain in the books, in the literature, in our minds but very importantly in our hearts."</p></div><div id="b-thal.Author_History"><h3>Author History</h3><p>Antonio Cao, MD; Consiglio Nazionale delle Ricerche (2000-2012)<br />Renzo Galanello, MD; Ospedale Regionale Microcitemie (2000-2013)<br />Raffaella Origa, MD (2013-present)</p></div><div id="b-thal.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>25 January 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 May 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 January 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 June 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 October 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 June 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 April 2003 (ac) Revision</div></li><li class="half_rhythm"><div>18 March 2003 (tk) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 September 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>March 2000 (ac) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1426</span><span class="label">PMID: <a href="/pubmed/20301599" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301599</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bpan/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bietti-cd/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1426&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1426/?report=reader">PubReader</a></li><li><a href="/books/NBK1426/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1426" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1426" style="display:none" title="Cite this Page"><div class="bk_tt">Origa R. Beta-Thalassemia. 2000 Sep 28 [Updated 2018 Jan 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1426/pdf/Bookshelf_NBK1426.pdf">PDF version of this page</a> (594K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#b-thal.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#b-thal.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#b-thal.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#b-thal.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#b-thal.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#b-thal.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#b-thal.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#b-thal.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#b-thal.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#b-thal.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#b-thal.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#b-thal.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3043[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HBB</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1426+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1499088" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1499088" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1499088" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1499088" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301608" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R, Moi P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301551" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sickle Cell Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sickle Cell Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bender MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24624460" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kalfa TA, Connor JA, Begtrup AH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20492708" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-thalassemia.</a><span class="source">[Orphanet J Rare Dis. 2010]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-thalassemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Galanello R, Origa R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2010 May 21; 5:11. Epub 2010 May 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301599" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301599" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0413cd75f66d18aa0d69cc">Beta-Thalassemia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Beta-Thalassemia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:58:37-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE881B6CE04117F10000000000EF005D&amp;ncbi_session=CE881B6CE0413CD1_0239SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1426%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1426&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1426/&amp;ncbi_pagename=Beta-Thalassemia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE881B6CE0413CD1_0239SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>